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“Man carries the world in his head, the whole astronomy and chemistry 
suspended in a thought.  Because the history of nature is charactered in his brain, 
therefore he is the prophet and discoverer of her secrets.  Every known fact in 
natural science was divined by the presentiment of somebody, before it was 
actually verified.” 
     Ralph Waldo Emerson 1803-1882  
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“When I first smoked it, I didn't notice the effects too much…As I continued to 
use, meth gave me energy and alertness… It wasn't long after I started using meth 
that I could no longer get high like I used to. Instead, I got paranoid, scared and 
uncomfortable and I started distancing myself from friends and family. I was 
caught for stealing, possession of marijuana and numerous underage-
consumption violations. I found myself in and out of juvenile detention centers 
and rehab clinics... I just kept thinking I was different in some way because all my 
friends seemed to be able to handle the drugs just fine.” 
 –Recovering Addict, Partnership for a Drug Free America 
 
The preceding passage highlights a familiar and all too common scenario 
affecting millions of people each year – the initiation of drug use and the transition to 
substance dependence. A substantial percentage of US 12th graders reported both being 
able to ‘fairly easily’ access alcohol (92.2%) or other illicit drugs (83.9%) and having 
tried alcohol (71.9%) or illicit drugs (47.4%) within their lifetime (Johnston et al., 2009).  
However, though large percentages of the population are exposed to drugs of abuse only 
a fraction (~9%) eventually develop substance abuse or dependence (Johnston et al., 
2009; SAMHSA, 2009).   
Why is it then, given that drugs are freely available, only a portion of the 
population seeks out drugs and of these individuals only a small percentage eventually 
develops substance abuse and dependence problems? The recognition of individual 
variation to the effects of substances of abuse has been realized for some time. Indeed, 
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published accounts can be found more than 300 years ago articulating the presence of 
individual differences in the effects of opiates (Jones, 1700; Bigelow, 1822; Crothers, 
1893), alcohol (Crothers, 1893), and cocaine (Brainerd, 1891).  Through decades of 
concentrated research, it is now realized that the vulnerability to use and abuse drugs 
arises from a complex, interacting set of factors extending across genetic, environmental, 
psychological and biological realms.   
 To adequately introduce my dissertation topic, I will describe some of the 
commonly discussed environmental, trait and genetic factors associated with an increased 
risk to initiate and maintain drug use. The neurobiological pathway theorized to underlie 
some of the effects of these factors on drug use risk will then be depicted and outlined as 
it relates to an animal model of drug use vulnerability.  Parallels between animal models 
and human research will be discussed ending with several proposals for examining 
substance use vulnerability in humans. 
 
Epidemiological, Developmental, and Genetic Studies on Drug Use Liability 
Risk and resilience factors, in this context, describe characteristics present prior to 
the onset of addiction, which are associated with an increased or decreased probability of 
drug abuse.  These characteristics, henceforth referred to as susceptibility factors, may 
influence the initiation of drug use, the reinforcing effects of drugs and may ultimately 
predict substance dependence.  A variety of long-term, epidemiological, longitudinal and 
genetic studies have been conducted with the purpose of uncovering which factors 
determine future drug use. 
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Social and Environmental Factors 
In the initiation stage of addiction, individuals experiment with drugs either as a 
result of curiosity or circumstance.  Among those drawn to use drugs out of interest, 
social and environmental factors are most frequently attributed to their initial drug taking 
behavior.   
Familial and peer relationships are regularly cited as important factors in 
mediating initial drug use. This is particularly true among adolescents and young adults 
where the risk of illicit drug initiation is the highest. Poor familial bonds, family conflict 
and associating with antisocial peers are all significant predictors of future drug use (e.g. 
(Guo et al., 2002)).  In addition, having family members who use drugs and affiliating 
with peers who use drugs are associated with faster initiation of substances use (see 
(Newcomb et al., 1986; Boyd and Mieczkowski, 1990; Levy and Pierce, 1990; Burton et 
al., 1996; Hussong and Chassin, 1997; Miller and Miller, 1997; Galea et al., 2004; 
Dawson, 2006).  Social influences appear, from a psychological perspective, to mediate 
drug use by manipulating opportunity to access drugs, shaping attitudes regarding 
substance use and acting as a source of conflict where drugs are used as a means to cope.  
To the latter point, stress has long been recognized as a key factor in the initiation of 
drugs use.  The use of drugs as a coping mechanism is frequently encountered in the 
literature, particularly among persons dealing with traumatic events such as physical 
abuse, sexual abuse, and frequent geographic relocation (e.g. (Harrison et al., 1997; 
DeWit, 1998; Hien et al., 2005)).  Indeed, development of positive coping strategies and 
social problem solving skills serve as protective factors against initiation and increased 
consumption (e.g. (Hussong and Chassin, 1997; Siqueira et al., 2001; Wills et al., 2001; 
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Kaplow et al., 2002)) while disengaging coping strategies (e.g. reacting with anger, 
hanging out with friends) are associated with escalated substance use (Wills et al., 2001). 
Stressful life events can increase drug use and influence escalation from use to 
abuse (see reviews (Kaplan et al., 1986; Wills et al., 1996; Sinha, 2001; Wills et al., 
2001; Butters, 2002; de Wit et al., 2003; Fishbein et al., 2006; Sinha, 2008).  Recent 
stress as well as the total number of stressful experiences reported over a life time is 
associated with increased risk of drug dependence  (see review (Sinha, 2008)).  
Furthermore, in dependent individuals drug consumption tends to increase following 
exposure to stressful situations.  In periods of abstinence, stress can elicit craving and 
relapse in heroin addicts, smokers, alcoholics and cocaine users (Miller et al., 1974; 
Sinha et al., 1999; Sinha et al., 2000; McMahon, 2001; Sinha, 2001).  While stress may 
instigate drug use as a means to cope with current adverse states (e.g. dealing with 
personal problems, craving, withdrawal) as will be described later stress is also a potent 
mediator of neurobiological functioning. 
 
Gender Differences 
According to the most recent National Survey on Drug Use and Health in persons 
over the age of 12, men currently show higher rates of illicit drug use and lifetime 
prevalence of drug use relative to women, though there was an overall significant 
increase in illicit drug use among females from the previous year (2007, 5.8%; 2008 
6.3%; (SAMHSA, 2009).  The rates of dependence in persons over the age of 12 are also 
higher in men relative to women (men, 11.5%; women, 6.4%).  Though in adolescents 
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between the ages of 12 and 17 the rate of dependence is more similar (men, 8.2%;women, 
7.0%) (SAMHSA, 2009). 
Though women generally show lower rates of substance use and dependence, the 
escalation from initial use to compulsive use is thought to occur much more rapidly in 
women (see (Becker et al., 2007)). Women more quickly develop substance abuse 
problems and enroll into substance abuse treatment sooner relative to men (Haas and 
Peters, 2000; Hernandez-Avila et al., 2004)).  The consequences of drug taking in 
females are also more severe; for instance in alcoholism, mortality rates for women are 
higher then men and women develop alcohol related medical issues faster then men (e.g. 
(Saunders et al., 1981; Bradley et al., 1998)). 
The effects of drugs on women and men can also be quite different.  At moderate 
and high alcohol drinking levels, women show greater impairments in short and long 
term memory and divided attention (Mumenthaler et al., 1999).  Following intranasal 
administration of cocaine, women report more nervousness and take longer to notice its 
effects compared to men (Kosten et al., 1996; Lukas et al., 1996).  Exposure to drug 
related cues also elicits greater craving in cocaine abusing women (Robbins et al., 1999).  
Interestingly, the effects of drug described by women appear to vary by phase of 
menstrual cycle. Women give higher positive subjective ratings for amphetamine in their 
follicular phase relative to their luteal phase (Justice and de Wit, 1999; White et al., 
2002), lower positive subjective effects for amphetamine when in their luteal phase, and 
give more similar ratings to men in their follicular phase (White et al., 2002).  Similar 
effects are noted for smoked cocaine where men report more positive drug effects 
compared with women in the luteal phase but not when compared to women in their 
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follicular phase (Sofuoglu et al., 1999).  In addition, smoking cessation attempts among 
women are more successful when attempted during the luteal phase (Allen et al., 2008). 
 How exactly sex plays a role in determining substance abuse liability is not 
known but as will be explored later differences in stress responsivity may be partially 
accountable (Becker et al., 2007). 
 
Psychiatric Conditions 
Psychological conditions have received some attention in regards to substance use 
initiation. There is a high degree of co-morbidity between substance abuse and 
psychiatric disorders. According to the most recent National Survey on Drug Use and 
Health, persons over the age of 18 with a serious mental illness (e.g. diagnosed mental 
disorders, other than substance dependence, based on DSM-IV criteria) were much more 
likely to have used an illicit substance in the past year than those without a psychiatric 
condition (30.3% vs. 12.9%, (SAMHSA, 2009)).  In addition the rate of dependence 
among those with psychiatric problems is much higher (25.2% vs. 8.3%, (SAMHSA, 
2009)). 
Attention-deficit hyperactivity disorder, conduct disorder, oppositional defiant 
disorder, and major depressive disorder all predict early onset of substance use (Sihvola 
et al., 2008; Munafò et al., 2008b; Elkins et al., 2007; King and Chassin, 2004; Cohen et 
al., 2007).  Early initiation of drug use is also predicted by personality disorders such as 
paranoid and borderline personality disorders (Cohen et al., 2007).  Diagnosis of 
posttraumatic stress disorder (PTSD) and schizophrenia is also associated with 
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significantly increased risk of developing substance abuse and dependence (see (Chilcoat 
and Breslau, 1998b, a; Volkow, 2009)). 
 The basis for the linkage between substance abuse and mental illness is not 
entirely clear, however, it has been postulated that these disorders share common 
underlying biological substrates (Volkow, 2001; Volkow, 2009). 
 
Trait Characteristics 
Certain personality characteristics predict earlier initiation to substance use and 
heightened sensitivity to the effects of drugs. Impulsiveness represents one of the most 
frequently implicated traits in this regard (e.g. (Dawe and Loxton, 2004)). Though often 
referred to as a single trait, impulsiveness is a multidimensional concept consisting of 
characteristics that include sensation seeking, lack of planning, lack of persistence and 
urgency (Whiteside and Lynam, 2001; Smith et al., 2007).  The planning dimension, 
frequently measured as the devaluation of rewards as a function of time (i.e. delayed 
discounting), predicts problem behaviors like drinking, problem gambling, and binge 
eating and the sensation-seeking dimension predicts risk taking in general (Fischer et al., 
2004; Smith et al., 2007).  Expressing high levels of impulsiveness either in the 
novelty/sensation seeking or non-planning dimensions are associated with earlier 
initiation of substance use (Masse and Tremblay, 1997; Kollins, 2003; Ernst et al., 2006; 
Wills et al., 2006; Audrain-McGovern et al., 2009).  The subjective effects of nicotine 
and amphetamine are also related to measures of sensation seeking in non-users 
(Hutchison et al., 1999; Perkins et al., 2000; Kelly et al., 2006; Stoops et al., 2007). 
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Individuals exhibiting more impulsive or sensation-seeking behavior are at greater 
risk to develop substance use problems and be diagnosed with a substance use disorder 
(e.g. (Cloninger et al., 1988; Caspi et al., 1996; Zuckerman et al., 2000; Ruiz et al., 
2003)). Indeed, severity of dependence is associated with measures of delayed 
discounting (see review (Reynolds, 2006)).  
Personality can also influence relapse and craving. For instance, impulsive 
smokers have more trouble inhibiting their smoking and show more rapid relapse than 
their counterparts (Mitchell, 1999; Doran et al., 2004). In addition, smokers exhibiting 
high sensation-seeking or impulsive characteristics demonstrate greater craving following 
exposure to smoking cues (Doran et al., 2007; Doran et al., 2009).  High impulsivity in 
adolescence predicts poorer outcomes in individuals attempting to quit smoking 
(Krishnan-Sarin et al., 2007). 
 In sum, these data indicate that personality characteristics can significantly 
influence substance use and abuse susceptibility.  The exact mechanisms behind 
personalities’ influence on drug seeking and use are not well understood, though as will 




Much work indicates that the heritability of addiction itself is roughly 33-72% 
(see (Goldman et al., 2005; Li and Burmeister, 2009)).  The use of linkage mapping, 
candidate gene association and genome wide association analyses has enabled the 
identification of multiple genes associated with an increased risk to develop addiction.  
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As recently reviewed by several groups, potential gene candidates for addiction 
susceptibility include gene variants in dopamine, opioid, GABA, and serotonin pathways 
(Goldman et al., 2005; Kreek et al., 2005; Li and Burmeister, 2009).  
How might genetic variability influence susceptibility to addiction?  As I will 
briefly discuss below, genetic variation can directly alter the metabolism of the drug 
itself, influence the functioning of neurobiological pathways that may underlie addiction 




The positive reinforcing effects of drugs, a reasonable predictor of abuse potential 
(Foltin and Fischman, 1991), can vary quite dramatically from individual to individual.  
Inherited conditions have been demonstrated to dramatically alter the initial effects of 
drugs, which can impact future drug use. One striking example of this comes from a 
mutation in the aldehyde dehydrogenase gene (ALDH2).  Normally, when alcohol is 
consumed it is metabolized within the liver into acetate by two enzymes: alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).  ADH first converts 
alcohol into acetylaldehyde and ALDH converts this into acetate.  If ALDH is not 
functioning properly, toxic levels of acetylaldehyde accumulate and the result is “flushing 
syndrome” where among other negative reactions, the person experiences facial flushing, 
dizziness, and nausea (see (McGue, 1999)).  Carriers of this inactivated enzyme are 
relatively protected against alcohol addiction, however, they still initiate drinking at the 
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same levels (McGue, 1999; Hampton, 2006) and given the right set of conditions will 
drink despite possessing this resilience factor (see overview (Hampton, 2006)).   
Similar findings have been noted for polymorphisms of cytochrome P450 genes. 
Major enzymes involved in drug metabolism, cytochrome P450 enzymes transform 
carbon-rich molecules into a form that is more easily excreted from the body.  Within our 
collection of cytochrome P450 enzymes, exist CYP2D6, which converts codeine to its 
active form morphine, and CYP2A6, which converts nicotine into its inactive form 
cotinine.  Some investigations have observed that individuals who are deficient in 
CYP2D6 metabolism are protected, albeit incompletely, against opioid dependence, 
though this assertion is still under discussion (Tyndale et al., 1997; Mikus et al., 1998) 
and in addition, those with reduced or null CYP2A6 activity tend to smoke less than their 
wild-type counterparts, possibly due to the higher levels of nicotine afforded by each 
cigarette, and are more likely to quit smoking (see review (Ray et al., 2009)).  Individuals 
with a genetic predisposition for faster metabolism, on the other hand, may be at 
increased risk to develop substance dependence (see review (Ray et al., 2009)). 
 
Neurotransmitter Systems 
Dopamine acts at several dopamine receptor subtypes (D1-D5) and each show 
slightly different expression patterns throughout the brain (see (Jaber et al., 1996)).  
Multiple genetic studies have studied each of these receptor subtypes and have attempted 
to associate genetic variation with various measures of substance abuse and several 
interesting observations have been made.  
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Genetic variations at D2-like receptors, which include subtypes D2-D4, are most 
frequently associated with addictive behaviors. The dopamine D2 receptor (DRD2) 
polymorphisms TaqIA (and in ANKK1, a neighboring gene involved in signal 
transduction) and TaqIB, have been associated with alcoholism and opioid dependence 
respectively (see throughout review by (Le Foll et al., 2009)). These polymorphisms are 
also related to the age of initiation and progression of smoking in adolescents and predict 
higher consumption and craving of opiates following exposure to drug cues (Laucht et 
al., 2008; Le Foll et al., 2009).  Additionally, variation at the dopamine D3 receptor 
(DRD3) gene and the dopamine D4 receptor (DRD4) variable number tandem repeat 
(VNTR) polymorphism have been linked to nicotine dependence (Le Foll et al., 2009).  
Though most work has been carried out on D2-like receptors, some studies have 
indicated that polymorphisms in D1-like receptors, which include D1 and D5 subtypes, 
are been associated with alcohol dependence, heavy smoking, and greater consumption of 
heroin (see review (Le Foll et al., 2009)). There have also been reports linking genes for 
two enzymes responsible for catecholamine breakdown (which includes dopamine) to 
addiction risk, catechol-o-methyl transferase (COMT) and monoamine oxidase (MAO).  
A common polymorphism in COMT results in a valine to methionine change at position 
158, which reduces COMT enzymatic activity dramatically.  This mutation has been 
associated with alcoholism and social drinking (see (Kauhanen et al., 2000; Kreek et al., 
2005)).  A variable number tandem repeat (VNTR) in the MAOA gene has also been 
linked to alcoholism (see (Kreek et al., 2005)). 
Beyond dopamine, genetic variation at opioidergic receptors has also been linked 
to substance dependence. There are several receptor subtypes to which endogenous 
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opioids bind to – μ, κ, δ, and orphan.  The endogenous opioids, which include 
endorphins, enkephalins, nociceptins, endomorphins and dynorphins have distinct 
preferences to the receptor types, which they bind to.  Endorphins, endomorphins and 
enkephalins display preferences to μ- and δ- receptors whereas dynorphin and nociceptin 
principally bind to κ- and orphan receptors, respectively. 
In regards to genetic association with substance dependence, one of the best-
studied receptor subtypes is the μ-opioid receptor.  Within the μ-opioid receptor gene 
(OPRM1) a missense single nucleotide polymorphism (SNP) results in an asparagine to 
aspartic acid substitution at residue 40 (typically referred to as the A118G 
polymorphism).  This alteration results in enhanced binding of β-endorphin at the μ-
opioid receptor (Bond et al., 1998).  This A118G polymorphism has been associated with 
opioid addiction and alcoholism (Szeto et al., 2001; Bart et al., 2004; Bart et al., 2005; 
Drakenberg et al., 2006); however some investigations have failed to observe this 
(Crowley et al., 2003; Arias et al., 2006) and others have identified associations between 
nearby SNPs but not A118G with opioid addiction (Levran et al., 2008). A more 
consistent association has been observed between this polymorphism and the treatment 
efficacy of naltrexone in alcoholics (e.g. (Oslin et al., 2003; Anton et al., 2008; Kim et 
al., 2009)). 
There are dozens of other examples from genes within serotonergic, cholinergic 
and GABAergic systems to neurotrophic factors and even signaling molecules within the 
immune system which are also associated with substance abuse (Goldman et al., 2005; 
Kreek et al., 2005; Li and Burmeister, 2009). This discussion represents only a short list 




Estimates on the heritability of personality fall roughly between 30-50% 
(Cloninger et al., 1988; Bouchard, 1994). Multiple genetic variants have been associated 
with the expression of particular trait characteristics shown to contribute to both the 
initiation and maintenance of drug use.   
Genes from multiple neurotransmitter systems show linkage with both impulsivity 
and addiction, including dopamine, serotonin and GABA (Kreek et al., 2005). For 
instance, a recent meta-analysis by Munafo demonstrated an association between 
measures of novelty-seeking and impulsivity and the DRD4 C-521T polymorphism 
(Munafò et al., 2008a).  Similarly, within the DRD1 gene, a 5’ untranslated region 
polymorphism called Ddel has been associated with sensation seeking in alcoholic 
patients (Limosin et al., 2003) and DRD3 variants have been associated with opioid 
dependence in individuals with high sensation seeking scores (Duaux et al., 1998).   
Along these same lines, associations between traits impulsivity and novelty 
seeking and genes responsible for the degradation of catecholamines like dopamine, 
COMT and MAOA, have also been described (e.g. (Manuck et al., 2000; Contini et al., 
2006; Golimbet et al., 2007)). Beyond dopaminergic genes, a variety of genetic studies 
have linked serotonin and GABAergic variants to impulsive and novelty-seeking traits 
including: TPH1, SERT, GABARA1, GABARA6, GABARB1 (see review (Kreek et al., 
2005)).  
 
Summary of Genetic Findings 
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In conclusion, genetic variability appears to significantly contribute to some of the 
drug taking variability in humans and is related to some measures of trait characteristics.   
What should be gleaned from these studies is there is no one gene responsible for 
an individual’s passage into addiction, nor does any one gene confer absolute 
vulnerability or resilience to use drugs. Though some individuals exhibit relative 
insensitivity to the positive reinforcing effects and relative sensitivity to the toxic, 
negative effects of a drug, this does not inevitably lead to cessation of drug use, nor do 
differences in drug metabolism inexorably govern use and non use, rather an individuals 
consumption seems determined not only by their genetic sensitivities but owing to other 
intervening factors as well.  
It appears that addiction results from a complex interplay of multiple genetic and 
environmental factors.  These data indicate that variation within multiple 
neurotransmitter systems may be in part responsible for future drug use and abuse. 
Identification of other gene targets is therefore of significant interest as it may lead to 
better understand to the biological mechanisms underlying addiction susceptibility.  
 
Susceptibility Factor Summary 
To summarize, there are a number of different factors that can affect initial drug 
use, subjective effects to the drug itself, and influence the progression to substance 
dependence.  While psychological, social and environmental factors may provide some 
individuals with greater exposure and opportunity for experimentation, there is data to 
suggest the impact of these factors go beyond simple differences in availability and social 
acceptability (see (Dube et al., 2003)) and may involve biological processes.  Indeed, the 
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initiation and maintenance of substance use appears to be heritable (e.g. (Sullivan and 
Kendler, 1999; Heath and Martin, 1993; Kendler et al., 1999)).  
While there has been quite a bit of work done uncovering factors that modify 
individual vulnerability, understanding the mechanisms that underlie these differences in 
susceptibility, particularly in humans, are not completely understood.  For many of the 
factors discussed, while they may affect drug use by exposure, opportunity and 
metabolism of the drug itself, it is possible they may also exert their effect by influencing 
central biological processes.  Indeed, one could hypothesize that variation brought on by 
susceptibility characteristics within the neural pathways responsible for reward or 
motivation could certainly impact the drive of an organism towards appealing drug 
stimuli. This, in fact, appears to be the case.   
As I will discuss in the upcoming passages, certain trait and environmental 
susceptibility factors have been associated with activity within a particular 
neurobiological pathway responsible for reward and drive, the motivational circuitry.  
Before describing that research, I will first delve into a description of the motivational 
circuitry’s function and organization to provide a framework for discussing those studies. 
 
Motivational Circuitry 
Work done in the 1950s first established the presence of an anatomically distinct 
‘reward’ circuit (Olds and Milner, 1954). In their groundbreaking and serendipitous 
study, Olds and Milner implanted electrodes into the brains of rats and presented them 
with the opportunity to self-administer electrical stimulation by way of a lever press.  
They observed that when the electrodes were placed within certain brain regions, the rats 
16 
would press a lever persistently, sometimes thousands of times an hour (Olds and Milner, 
1954).  From these observations, Olds and Milner surmised they had inadvertently 
stumbled upon a circuit responsible for reward. Later work would establish the region 
stimulated was near the ventral striatum (Milner, 1989) and that given the opportunity 
humans would also self-administer electrical stimulation in equivalent regions (Heath, 
1963). 
A few years following Olds and Milner’s discovery, Falack and Hillarp detected the 
cell bodies of dopaminergic neurons within the midbrain which projected to the ventral 
striatum (Falck and Hillarp, 1959) and it was found that dopaminergic antagonists and 
lesions to the ventral tegmental area (VTA) would result in a substantial reduction in self-
stimulation (Rolls et al., 1974; Fibiger et al., 1987). Later studies would expand upon that 
and demonstrate that in response to natural or artificial rewards (such as food, sex, drugs) 
neurons within the VTA become activated which results in dopaminergic release within 
the nucleus accumbens (NAC).  Thus, it appeared that dopamine, particularly within this 
mesolimbic circuitry, was central to reward. Decades later, this circuitry would be 
elaborated upon and conceptualized more generally as motivational circuitry, broadened 
to embody the influence of other neurotransmitter systems (e.g. opioids, GABA, 
glutamate) and expanded to include a number of other regions including:  prefrontal 
cortex, hypothalamus, amygdala, and ventral pallidum.  
 
Motivational circuitry anatomy 
Motivated behavior emerges as a result of activity within a series of interconnected 
regions including the ventral tegmental area, nucleus accumbens, amygdala, and 
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prefrontal cortex, which interact to signal the significance of stimuli, assign incentive 
value and select appropriate action ((Kalivas and Volkow, 2005), see Figure 1).  
 
 
Figure 1. Schematic of critical brain structures involved in motivated behavior and their connections.  
(adapted from (Kalivas and Nakamura, 1999) and (Blum et al., 2008)). Ventral tegmental area (VTA), 
nucleus accumbens (NAc), ventral pallidum (VP), amygdala (AmyG) and hypothalamus. 
 
Key to the regulation of motivated behavior is dopaminergic neurotransmission 
within the nucleus accumbens.  As will be described below and is illustrated in the figure 
above, the nucleus accumbens receives information from sites across the brain.  It is 
hypothesized that dopamine influences the integration of activity arriving at this locus.  
Indeed, critical to the expression of motivated behavior is the activity from dopaminergic 
neurons (A10) located within the VTA.  These neurons project from the VTA to the 
nucleus accumbens to form the central pathway of the mesolimbic dopamine system.  
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The nucleus accumbens does not act alone but in concert with regions throughout 
the brain to regulate motivated behavior.  In addition to the dopaminergic projection from 
the VTA to the nucleus accumbens, the VTA also projects to the hippocampus, 
amygdala, ventral pallidum, and various cortical areas including the prefrontal and 
cingulate cortex.  These regions and their interconnections are collectively referred to as 
mesocorticolimbic pathways. 
To delve into this circuit a bit more deeply, the amygdala, hippocampus and 
prefrontal cortex all send glutamatergic projections to the nucleus accumbens and VTA 
which activate dopamine neurons within the VTA and the dopaminoceptive neurons 
within the nucleus accumbens (see Figure 1).  The nucleus accumbens in turn sends 
GABAergic projections to the VTA, ventral pallidum and substantia nigra (Haber et al., 
1990).  The ventral pallidum sends GABAergic efferents to the VTA, the 
pedunculopontine nucleus, which influences locomotor activity and to the medial dorsal 
nucleus of the thalamus, which ultimately feeds back to the prefrontal cortex.   
As illustrated above, the nucleus accumbens receives projections from throughout 
the brain and is proposed to act in an integrative capacity assimilating goal directed 
information from the prefrontal cortex, environmental context from the hippocampus, and 
emotional significance from amygdala (Mogenson and Yang, 1991; Kalivas and 
Nakamura, 1999).  In addition, the nucleus accumbens output to the ventral pallidum1 and 
substantia nigra are believed to influence motor planning.  As a result of these 
                                                 
1 Footnote:  The ventral pallidum is being increasingly recognized as a critical reward region.  In addition 
to the connections described above the ventral pallidum also receives inputs from a variety of limbic and 
midbrain structures (Smith et al., 2009).  It appears that together with the nucleus accumbens, the ventral 
pallidum is key to the manifestation of ‘liking’ whereas the nucleus accumbens is crucial for ‘wanting’ 
(Tindell et al., 2006; Smith and Berridge, 2007; Tindell et al., 2009)). 
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connections, the nucleus accumbens is believed to be crucial in the translation of will into 
action (Mogenson and Yang, 1991; Kalivas and Nakamura, 1999). 
The mesocorticolimbic dopamine system does not exist in a vacuum, rather it 
interacts with a number of different neural systems to regulate behavior. Below I will 
discuss how the opioid system, HPA axis and other neuropeptide systems can influence 
activity within this pathway with specific attention paid to the VTA and nucleus 
accumbens given their central roles in motivated behavior.  
 
Opioid System Interactions  
Opioidergic activity acts as a critical regulator in the mesocorticolimbic circuitry.  
As described earlier, there are several main classes of endogenous opioids that display 
different preferences for the receptor subtype they bind to, but for the purposes of this 
discussion, the main opioid receptor of interest is the μ-opioid receptor, which has been 
extensively linked with stress, reward and addiction. Two main classes of endogenous 
opioid act at the µ-opioid receptor: endorphins and enkephalins, which are a product of 
the propiomelanocortin (POMC) gene and proenkephalin gene respectively. µ-opioid 
receptors are localized through the motivational circuitry including within various areas 
within the limbic system including the hippocampus and amygdala, prefrontal cortex, 
thalamus, the dorsal and ventral striatum as well as within the VTA (Frost et al., 1985; 
German et al., 1993). 
The μ-opioid receptor belongs to the G-protein-coupled receptor (GPCR) family, 
which transduces opioid binding signals into an intracellular signal (G-protein 
activation). Activation of this receptor results in the inhibition of adenlyl cyclase and 
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voltage-gated Ca2+ channels and the stimulation of inwardly-rectifying K+ channels, the 
net result being, inhibition of transmitter release. 
Endogenous opioids activity can influence the mesocorticolimbic circuitry in 
several ways, though principally they function via disinhibition.  For example, the 
neuronal population of the VTA is mostly comprised of dopaminergic and GABAergic 
neurons.  These VTA dopaminergic neurons are tonically inhibited by the activity of 
GABA interneurons (Johnson and North, 1992; Spanagel et al., 1992). µ-opioid receptors 
are localized on GABAergic interneurons and activation of these receptors releases the 
VTA dopamine neurons from inhibition and promotes firing (Johnson and North, 1992; 
Spanagel et al., 1992).   
µ-opioid neurotransmission can have effects on dopaminergic activity outside of the 
VTA; for instance, µ-opioid receptors have been shown to colocalize with D2 receptors 
in the striatum (Ambrose et al., 2004).  In addition, there are also enkephalin projections 
from the nucleus accumbens to the ventral pallidum and VTA and endorphin projections 
from the hypothalamus to the nucleus accumbens (Bloom et al., 1978; Finley et al., 1981; 
Kalivas et al., 1993).  
 
Stress, Dopamine and Neuropeptide Interactions in the Mesocorticolimbic Pathway 
Stress 
In response to a stressor a myriad of biological reactions occur.  Along the 
hypothalamic-pituitary-adrenal (HPA) axis perception of stress results in release of 
corticotrophin releasing factor (CRF) from the hypothalamus, this stimulates the release 
of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland into the 
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bloodstream which leads to release of glucocorticoids from the adrenal glands (McEwen 
et al., 1986). The effects of stress are not limited to the HPA axis and can result in 
widespread changes throughout the brain. 
More than thirty years ago, it was recognized that stress could increase dopamine 
release within the mesolimbic circuitry (Thierry et al., 1976).  These effects appear to be 
mediated through the actions of glucocorticoids and CRF on a variety of regions. 
Corticosteroid receptors are widely distributed throughout the brain including within the 
prefrontal cortex, hippocampus, amygdala and on A10 dopamine neurons within the 
midbrain (Härfstrand et al., 1986; Seckl et al., 1991). CRF receptors are also found in 
extrahypophysal regions, in particular within the hippocampus and amygdala (Chalmers 
et al., 1996; Van Pett et al., 2000). 
 Stress and glucocorticoid administration can enhance dopamine release within the 
nucleus accumbens (Kalivas and Duffy, 1995; Piazza et al., 1996). In addition, a 
reduction in both basal dopamine concentration and stress induced dopamine release 
within the nucleus accumbens is observed following adrenalectomy (Piazza et al., 1996; 
Rouge-Pont et al., 1998; Barrot et al., 2001). In addition to glucocorticoid actions at the 
nucleus accumbens, regions projecting to the nucleus accumbens including the prefrontal 
cortex, hippocampus and amygdala are sensitive to the changing levels of circulating 
glucocorticoids.  Similarly, stress prompts CRF release from the VTA, which stimulates 
A10 dopaminergic neurons and enhances dopaminergic release in VTA projection areas 
(Ungless et al., 2003; Wang et al., 2005; Wanat et al., 2008).  Likewise, application of 
CRF receptor antagonists attenuates cocaine-induced dopaminergic activity in the 




Stress actions within the mesocorticolimbic system can be modulated by other 
systems.  The endogenous opioid system can serve both as a direct regulator of 
mesocorticolimbic activity and a modulator of HPA axis responsiveness.  In general, the 
endogenous opioid system has an inhibitory effect on stress responsiveness.  In response 
to stress, a large precursor protein called proopiomelanocortin (POMC) is synthesized 
and cleaved to produce several products including ACTH and the opioid peptide, beta-
endorphin (Guillemin et al., 1977). Both ACTH and beta-endorphin exert negative 
feedback on CRF release within the hypothalamus dampening the stress response. The 
interaction between µ-opioid system activity and stress responsiveness has been 
demonstrated through the administration of the opioid antagonist naloxone, which 
increases ACTH circulation possibly by facilitating CRF (Conaglen et al., 1985; Burnett 
et al., 1999). 
 
Oxytocin 
Another neuropeptide relevant to this discussion is oxytocin which has also been 
demonstrated to manipulate both stress and mesocorticolimbic activity. Oxytocin is a 
neuropeptide primarily synthesized within the paraventricular nuclei within the 
hypothalamus though it has been observed along with its receptors in a variety of 
extrahypothalamic brain regions including the amygdala, nucleus accumbens and ventral 
tegmental area (primate: (Fliers et al., 1986; Caffé et al., 1989; Loup et al., 1991), rat: 
(Brinton et al., 1984; Van Leeuwen et al., 1985; Krémarik et al., 1993). 
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Oxytocin is released in response to a variety of psychological and physical 
stressors where it appears to have anxiolytic effects and can influence both central and 
peripheral stress responsiveness (Lang et al., 1983; Jezova et al., 1995; Robinson et al., 
2002; Wigger and Neumann, 2002; Onaka, 2004). For example, chronic infusions of 
oxytocin can dose dependently lower plasma corticosterone concentrations following 
stress in ovariectomized female rats (Windle et al., 1997) whereas intracerebral infusion 
of oxytocin antagonists elevates stress-induced ACTH and corticosterone concentrations 
in response to a variety of stressors (e.g. (Neumann et al., 2000)).  Similar effects have 
been observed in humans where intranasal administration of oxytocin can reduce cortisol 
responses to psychological stressors (Heinrichs et al., 2003; Ditzen et al., 2009). 
Beyond its effects on HPA activity, oxytocin can influence central nervous system 
activity as well.  As mentioned earlier, oxytocin receptors are expressed throughout the 
brain.  In addition, oxytocin neurons within the hypothalamus project to 
extrahypothalamic regions including the ventral tegmental area (Sofroniew, 1983). 
Application of oxytocin into the VTA results in increases in extracellular dopamine 
concentrations in the nucleus accumbens and hypothalamus (Melis et al., 2007).  In 
addition, application of an oxytocin receptor antagonist intracerbroventricularly can 
severely diminish apomorphine-stimulated dopaminergic release in the nucleus 
accumbens (Succu et al., 2007).  
 
Summary of Motivational Circuitry Anatomy 
As the information presented thus far indicates, there are numerous systems that 
contribute to the functioning of the mesocorticolimbic circuitry. Central to this circuitry 
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lies dopaminergic activity within the nucleus accumbens, facilitated by VTA, which 
incorporates information from a variety of systems to promote motivated behavior – How 
does all this relate to substance abuse? 
All drugs of abuse increase dopaminergic release within the NAC (see (Nestler, 
2004)).  Repeated administration of drugs causes sensitization of dopamine release within 
this region.  This dopamine release is hypothesized to result in a progressive increase in 
the incentive value of the perceived stimuli, in effect increasing desire or “wanting” for 
the stimuli (Robinson and Berridge, 1993, 2000).  Environmental cues that were formerly 
paired with the drug can also elicit dopamine release and develop conditioned incentive 
properties as well (Robinson and Berridge, 1993, 2000).   
Objects imbued with incentive salience are more attractive and “wanted” and can 
influence motivated behavior, effectively “drawing” the individual to the drug or 
conditioned cue (Robinson and Berridge, 1993, 2000; Wise, 2004).  In the case of 
addiction, chronic activation of the mesolimbic system by drugs is hypothesized to result 
in neural sensitization where dopaminergic systems overreact in response to drugs and 
environmental cues resulting in compulsive desire to consume drugs (Robinson and 
Berridge, 1993, 2000). Thus, influencing activity within the nucleus accumbens and 
within related regions may influence the attribution of incentive salience, motivated 
responses and ultimately addictive behavior.   
A good question at this point in regards to the previous susceptibility conversation - 
Is there any evidence to suggest that individual differences in the activity of this region 
exist and are they associated with an increased propensity to use drugs?  And if so, do 
environmental, trait, or genetic characteristics play a role in influencing such activity?  
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The answer to these questions appears to be yes.  As work done by Piazza and colleagues 
demonstrated more than twenty years ago, certain characteristics are associated with an 
increased propensity to use drugs and this behavior is related to dopaminergic activity 
within the nucleus accumbens which can be influenced by multiple factors. 
  
Individual Differences in Motivational Circuitry: Animal Models 
Some of the early work establishing individual differences in the propensity to use 
and abuse drugs observed differences in dopaminergic activity within the nucleus 
accumbens.  When laboratory animals are placed in a novel environment, a mild stressor, 
Piazza and colleagues observed some animals would exhibit high rates of exploratory 
locomotion (High Responders, HR) and others would exhibit lower rates (Low 
Responders, LR) (Piazza et al., 1989).  If given the opportunity, HR rats learn to self-
administer psychostimulants faster than LR rats (e.g. (Piazza et al., 1989; Piazza et al., 
2000; Marinelli and White, 2000; Kabbaj et al., 2000; Kabbaj et al., 2001)).  Further 
study would show that HR rats exhibit increased DA turnover (Piazza et al., 1991b) and 
enhanced DA in response to cocaine in the nucleus accumbens (Hooks et al., 1991), and 
lower dopaminergic activity within the prefrontal cortex (Piazza et al., 1991b).  Little 
more than a decade after the original HR/LR observations, Dalley and colleagues 
observed that animals exhibiting high ‘waiting impulsivity’ demonstrated higher rates of 
cocaine self-administration and lower levels of DA D2/3 receptors in the ventral striatum 





Influence of Stress Responses 
 Following the observation that one can predict an animals’ vulnerability to self-
administer psychostimulants by monitoring their locomotor reactivity to a mild stressor, 
Piazza and colleagues further explored the role of stress in determining addictive 
behavior by monitoring the animals biological stress responses following exposure to a 
novel environment (Piazza et al., 1991a). Analyzing corticosterone secretion, the 
dominant glucocorticoid in rats, in HR and LR animals, it was found that HR rats exhibit 
greater and longer secretion of corticosterone in response to novelty then their LR 
counterparts and that the level of secretion in HR rats was related to their propensity to 
self administer amphetamine (Piazza et al., 1991a; Piazza et al., 1998a; Kabbaj et al., 
2000). Additionally, it was observed that the administration of exogenous corticosterone 
differentially affected the animals, reducing amphetamine intake in HR rats and 
enhancing it in LR rats (Piazza et al., 1991a). Later it was shown that administration of a 
glucocorticoid antagonist reduces cocaine self-administration (Deroche-Gamonet et al., 
2003). Further, deletion of glucocorticoid receptors on postsynaptic neurons of the 
dopamine system (existing primarily within the nucleus accumbens, dorsal striatum, and 
prefrontal cortex) reduces cocaine self-administration (Ambroggi et al., 2009). Together, 
these data are believed to demonstrate a potentiating role for corticosterone on self-
administration behavior (Piazza et al., 1991a).  
In addition to innate differences in stress-reactivity, the influence of 
environmental stress can also play an important role in self-administration behavior. 
Social stress increases psychostimulant self-administration as does exposure to prenatal 
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stress, repeated electric shocks and tail pinch (Piazza et al., 1990a; Deminière et al., 
1992; Goeders and Guerin, 1994; Haney et al., 1995). How stress modifies self-
administration behavior is still a somewhat open question however, modifications have 
been observed at the level of the mesolimbic circuitry following acute and chronic stress.  
 
Stress and Dopamine Interactions  
 As discussed earlier, exposure to stress has been observed to increase dopamine 
release within the mesolimbic circuitry (e.g. (Thierry et al., 1976; Abercrombie et al., 
1989)).  Repeated exposure to a stressor, like footshock, can result in enhanced activation 
of dopamine neurons within the nucleus accumbens to further stress encounters (Kalivas 
and Duffy, 1989); this is similar to what is observed in the sensitization of dopaminergic 
neurons to psychostimulants (e.g. (Robinson and Becker, 1986; Robinson et al., 1988; 
Kalivas and Duffy, 1989). The degree to which stress induces changes in dopaminergic 
activity appears to be somewhat dependent on glucocorticoid transmission. 
Adrenalectomy, which suppresses the secretion of glucocorticoids, has been 
demonstrated to dramatically reduce basal dopamine concentrations in stress- or drug-
induced dopamine release within the nucleus accumbens (Rouge-Pont et al., 1998; Barrot 
et al., 2000). Additionally, administration of glucocorticoid antagonists blocks the stress-
induced release of dopamine within the nucleus accumbens (Rouge-Pont et al., 1995).   
There are individual differences in the degree to which stress and corticosteroids 
induce dopaminergic release within the mesolimbic system. Returning to the HR/LR rats, 
intravenously administered corticosteroids induces increases in extracellular dopamine 
concentrations within the nucleus accumbens in both groups, though the increases tend to 
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be greater in the HR rats compared to the LR rats (Piazza and Le Moal, 1996).  Similar 
observations have been made in regards to stress-induced dopamine release whereby HR 
rats exhibit greater dopamine release relative to their counterparts (e.g. (Rouge-Pont et 
al., 1998)). Further, adrenalectomy eliminated the HR rats’ enhanced stress-induced 
increase of dopamine but the administration of corticosterone reinstated it (Rouge-Pont et 
al., 1998). 
 
Differences beyond dopamine 
Besides dopamine, other neurochemical differences have been noted in these 
animals.  For example, HR animals demonstrate increased pro-enkephalin gene 
expression in the shell of the nucleus accumbens compared to LR animals (Lucas et al., 
1998). The variation of endogenous opioid activity within the HR animals is likely 
intertwined with the differences in dopaminergic neurotransmission noted earlier.  As 
illustrated previously, there are substantial connections between the µ-opioid system and 
the dopaminergic system (see Figure 1).  µ-opioid receptors are located throughout the 
motivational circuitry, including on GABAergic neurons within the VTA (Garzón and 
Pickel, 2001, 2002).  As mentioned earlier, the action of µ-opioid receptors results is one 
of presynaptic inhibition, the result of activating µ-opioid receptors within the VTA is 
one of disinhibition, potentially resulting in greater dopamine release at the level of the 
nucleus accumbens (Johnson and North, 1992).  
In addition to the behavioral and biological differences observed between HR/LR 
rats, there may also be some genetic differences. The novelty-seeking characteristic 
which differentiates HR rats from LR rats can be selectively bred (Stead et al., 2006). 
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Also, the presentation of novelty seeking behavior seems to be unaffected by prenatal 
stress and maternal care though early life stress can alter stress-responsivity in a trait 
dependent manner (Stead et al., 2006; Clinton et al., 2008).  There also seem to be 
differences in gene expression: HR rats exhibit lower D2 receptor mRNA within the 
striatum (Hooks et al., 1994) which may account for the elevated dopamine levels within 
the striatum of HR rats (see review (Blanchard et al., 2009); lower CRF mRNA in the 
amygdala, which may have anxiolytic effects; higher CRF mRNA levels within the 
hypothalamus and decreased glucocorticoid receptor mRNA in the hippocampus, which 
may promote enhanced sensation seeking behavior (Kabbaj et al., 2000; Kabbaj, 2004).   
Sex also appears to play a role in determining differences in HR/LR behavior.  
Though there is scarce data in this area, in one report testing for cocaine self-
administration behavior, Davis and colleagues found that HR bred females self-
administered more cocaine than either HR-bred males or LR females or males (Davis et 
al., 2008).   
 
Summary 
It would appear that the manifestation of individual differences in drug self-
administration behavior among the high and low sensation-seeking animals is at least 
partially related to differences in stress responsiveness. Stress can modulate 
dopaminergic activity within the mesolimbic system and the degree to which this occurs 
is related to an individual rat’s vulnerability to self-administer drugs.  Differences 
between HR/LR rats were also identified within the endogenous opioid system, which 
has been shown to interact with both dopaminergic and stress systems.  The variation in 
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behavioral and biological activity noted between the HR and LR rats also appear to be 
heritable.  Thus, it has been observed that some of the same factors which have been 
shown to predispose/protect an individual to drug use (e.g. trait characteristics, genetic 
variability, exposure to stress) in humans are associated with variation in some measures 
of biological activity in animal models.  Are there any parallel findings in humans? 
 
Individual Differences in Motivational Circuitry: Human Data 
When compared to animal data there is a relative paucity of information available 
from human studies.  However, there have been some similarities noted between some of 
the animal work described earlier and data collected in humans.  
 
Studies in Current and Former Drug Addicts 
As thoroughly discussed earlier and thus won’t be repeated here, stress and 
personality characteristics contribute to initial and future drug use in humans as they do 
in animals.  To illustrate this point further, it has been demonstrated that stress reactivity 
can predict drug consumption and relapse among current drug users.  In particular, a 
higher cortisol response to stress predicts faster treatment dropout among current drug 
users (Daughters et al., 2009) and higher cocaine consumption following treatment 
(Sinha et al., 2006). In regards to trait characteristics, drug addicts tend to discount 
rewards more (a measure of non-planning impulsivity) than non-addicts though this 
improves as a result of drug abstinence (see review (Reynolds, 2006).  
 Some work indicates drug abuse in humans is also associated with 
neurobiological changes within the dopaminergic and opioidergic systems.  Examining 
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current and former drug addicts compared to healthy controls, numerous differences in 
dopaminergic activity have been noted particularly within the ventral striatum.  D2 
receptor availability is lower in the striatum in cocaine, methamphetamine, alcohol and 
opiate abusing subjects and appears to persist after withdrawal (Volkow et al., 1993; 
Hietala et al., 1994; Wang et al., 1997; Volkow et al., 1999a). Dopamine transporter 
(DAT) levels, responsible for the reuptake of dopamine from the synapse, have also been 
reported to be decreased in the striatum in alcoholics and methamphetamine users 
(Tupala et al., 2000; Tupala et al., 2001; Chang et al., 2007).  In addition, dopamine 
increases in the ventral striatum in response to methylphenidate are lower in cocaine and 
alcohol abusers possibly reflecting decreases in dopaminergic cell activity and sensitivity 
to stimulation by reward (Volkow et al., 2007).   
Abstinent alcoholics show an increase in µ-opioid receptor BP with the ventral 
striatum relative to control subjects, which correlates to alcohol craving (Heinz et al., 
2005), though other investigations have failed to demonstrate this (Bencherif et al., 
2004). Abstinent cocaine users also show increased µ-opioid receptor availability within 
a number of regions including the frontal cortex, anterior cingulate, thalamus and caudate 
relative to healthy controls; in addition, some of these increases are positively related to 
craving (Zubieta et al., 1996).  Furthermore, some of these differences have been found to 
persist many weeks post abstinence (Gorelick et al., 2005). 
 
Studying individuals at risk 
Though the data in current and former drug addicts provide some perspective on 
functional neurobiological differences between addicts and controls, it isn’t possible to 
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determine whether these differences are a consequence of drug consumption or 
predisposing factors to their use.  This difficulty is present even when studying abstinent 
drug users as drug use and possible lifestyle differences can result in a number of 
biological and psychological changes that may persist long after the drug abuse stops 
(Schuckit, 1987). 
In humans, determining whether variation in biological functioning is related to 
vulnerability to use drugs presents a significant challenge. Unlike animal studies, where 
environmental factors and exposure to drug can be tightly controlled and individual 
animals followed from initiation to compulsive use, this is completely unrealistic for 
human experimentation. The best method available to study vulnerability in humans has 
been the study of groups at high risk. As Shuckit described for the study of vulnerability 
for alcoholism, there are numerous ways of obtaining a sample of high risk individuals 
for study: 1) study children of drug users that were raised by non-drug dependent parents 
2) study non-affected relatives of drug-using families 3) study healthy, non-drug using 
individuals from the population which carry risk factors theorized to place them at higher 
risk for substance abuse (Schuckit, 1987). 
For the purpose of studying specific neurotransmitter activity, typically done 
using neuroimaging methods that involve the administration of a radioligand, the first 
method is not acceptable, as one cannot ethically perform these scans in children for the 
purposes of research, given the necessity for radiation exposure.  Other techniques, like 
functional magnetic resonance imaging can be used however, this only yields a general 
picture of the neurobiological functioning differences and does not allow for the 
determination of the specific neurochemical processes involved.  The second method 
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proposed would allow for the use of radioligands however identifying non-affected 
relatives of drug using families would involve a very complicated recruitment process 
and would require access to multiple generations of families.  The final method proposed, 
studying populations that carry risk factors, is by far the most common approach used 
and has yielded some interesting results. 
First, in the realm of stress responsiveness, several neuroimaging studies have 
observed stress induced increases in dopaminergic and opioidergic activity within the 
striatum in healthy volunteers (e.g. (Adler et al., 2000; Zubieta et al., 2001; Pruessner et 
al., 2004; Scott et al., 2006)).  Increases in dopaminergic activity has been reported to be 
affected by early life stress, specifically only those displaying low levels of maternal care 
appear to show significant release within the ventral striatum (Pruessner et al., 2004), 
however, this finding has failed to be replicated (Montgomery et al., 2006).  Other 
investigations indicate that exposure to high environmental stress blunts dopamine 
responsiveness, whereas low or moderate life stress blunts dopamine responsiveness in 
high impulsive individuals to a greater extent (Oswald et al., 2007). 
Second, increases in dopamine activity can also be elicited by administration of 
methylphenidate and amphetamine, which is related to the degree of ‘high’ reported in 
healthy volunteers, and associated with cortisol secretion (Volkow et al., 1999c; Leyton 
et al., 2002; Oswald et al., 2005; Oswald et al., 2007; Wand et al., 2007).  Along these 
same lines, Boileau and colleagues demonstrated long-lasting enhancement of 
amphetamine-induced dopamine release within the ventral striatum following repeated 
exposure to amphetamine (Boileau et al., 2006). In addition to associations with 
dopamine release, akin to the observations made by Dalley, Hooks and coworkers in rats, 
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lower D2 receptor levels are associated with greater positive subjective ratings in the 
effects of methylphenidate in healthy, non-drug using volunteers (Volkow et al., 1999b). 
Third, similar to the observations made in rats, trait characteristics of impulsivity, 
novelty- and sensation-seeking have been shown to be related to amphetamine-induced 
dopamine release within the ventral striatum and anterior cingulate in healthy human 
subjects, although the direction of these relationships vary by sex and by study (Leyton et 
al., 2002; Riccardi et al., 2006a; Oswald et al., 2007).  One study also reported an 
association between reward dependence and opioid receptor availability within the 
ventral striatum (Schreckenberger et al., 2008).  In addition, the degree of sensitization of 
dopamine release following repeated administration of amphetamine is predicted by 
measures of novelty seeking and impulsivity (Boileau et al., 2006).   
 
Current Directions 
 Clearly understanding the neurobiological mechanisms underlying susceptibility 
factors is of considerable interest. Given the substantial personal and societal costs 
resulting from substance abuse, it is of great relevance to uncover and understand the 
factors that convey resistance or resilience to drug abuse.  Thus far, it has been 
established that: 1) behavioral, environmental and genetic factors provide some 
susceptibility to drug use, 2) that biochemical variations particularly within the 
motivational circuitry may underlie these differences in vulnerability and 3) the data 
available in humans to this end is much more sparse and in need of expansion. 
 The work presented here attempts to further elucidate the association between 
activity within the motivational circuitry and the personal characteristics and experiences 
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that have been established to play an important role in determining vulnerability to abuse 
drugs in humans.  Personal attributes such as sex, personality, and genetic disposition will 
be considered along with external influences such as adverse life events.   
 These experiments utilize positron emission tomography, a neuroimaging technique 
employing the use of radiotracers, which allows metabolic processes to be studied in 
vivo. In doing so, we are able to track neurochemical activity for the systems of interest 
(i.e. dopaminergic and opioidergic).  Given the observations made earlier, which indicate 
that neural and behavioral activity in response to stress are useful predictors of 
vulnerability for self-administration behaviors, we will examine neurochemical activity 
changes during performance of a stress challenge that has been previously shown to 
result in increases in activity in both endogenous opioid and dopaminergic systems 
throughout the motivational circuitry (Zubieta et al., 2001; Scott et al., 2006). 
 First, we discuss how trait characteristics, specifically measures of non-planning 
impulsivity, are associated with µ-opioid receptor activity, expanding upon the former 
literature previously describing an association with dopaminergic functioning.  
 Second, these works will seek to expand upon and confirm some of the associations 
observed between susceptibility factors and dopaminergic system activity.  The influence 
of environmental factors on dopaminergic activity will be examined and determine if sex 
plays a significant role.   
 Finally, we will assess the impact of genetic variation of the oxytocin gene on 
stress-induced dopaminergic activity.  Though the activity of this gene has not been 
previously associated with increased vulnerability to use and abuse drugs, we wanted to 
move beyond the typically studied variation at dopaminergic and opioidergic genes and 
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identify a unique target.  The oxytocin gene is an interesting candidate in this regard.  As 
described earlier, oxytocin has effects on both stress and motivational system activity. 
In addition, oxytocin has been shown to facilitate a variety of social and reproductive 
behaviors that incorporate motivational systems including maternal behavior, pair 
bonding, and sexual behaviors (see (Donaldson and Young, 2008; Lee et al., 2009)).   
For example, oxytocin appears to influence the drive of a lactating dam to approach pups 
(e.g. (Pedersen et al., 1994) and in a number of compelling studies, oxytocin has been 
demonstrated to influence pair bonding among monogamous prairie voles, specifically 
impacting partner preference among females  (e.g. Williams et al., 1992, Insel and 
Hulihan, 1995).  The mechanisms underlying oxytocin’s ability to facilitate such 
behaviors are not completely understood, however, it has been postulated that resulting 
dopaminergic increase within the nucleus accumbens following stimulation by oxytocin 
may influence the incentive salience attribution to the pups, influencing a mother’s drive 
to their infant (Pedersen et al., 1994; Becker and Taylor, 2008).  Oxytocin can also alter 
central dopaminergic responses associated with non-social behaviors, such as addictive 
behaviors like self-administration, tolerance, and dependence (see (Sarnyai and Kovács, 
1994). In fact, increased oxytocin activity may provide some resilience to addictions (see 
(Kovács et al., 1998)).  Thus, it has been postulated that oxytocin, though it may have 
evolved as a mechanism to promote maternal, affiliative, and sexual behaviors key to an 
organisms reproductive success, it also serves to influence other types of motivated 
behavior, like drug taking (see (Becker and Taylor, 2008)).  Given this information, we 
examined how genetic variation at the oxytocin gene relates to stress-induced 
dopaminergic activity.   
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 Overall, this research seeks to observe how certain traits, environmental factors and 
genetic predispositions, associated with an increased risk to develop substance use 
problems, influence individual differences in dopaminergic and opioidergic 




Positron Emission Tomography Measures of Endogenous Opioid 
Neurotransmission and Impulsiveness Traits in Humans2 
 
There is substantial interest in the mechanistic understanding of traits that may 
predispose individuals to the development of specific behaviors or psychopathologies. 
Trait impulsivity has received substantial attention because of its association with risky 
behaviors (e.g., experimentation with drugs, sex, problem gambling, reckless driving), 
personality disorders, or even the mortality associated with the mood disorders. 
Impulsivity, though frequently referred to as a single trait, is better conceptualized as 
heterogeneous characteristic consisting of multiple dimensions that include sensation 
seeking, lack of planning, lack of persistence and urgency (Whiteside and Lynam, 2001; 
Smith et al., 2007).  The planning dimension in particular appears to be more strongly 
associated with negative risk taking (i.e. binge eating, problem gambling, (Smith et al., 
2007)).  The same holds true for the urgency dimension which predicts problem 
behaviors (problem gambling and drinking) whereas factors such as sensation seeking are 
perhaps more related to risk taking in general (Fischer et al., 2004; Smith et al., 2007).  
Impulsivity as it refers to pathological behavior has been well studied in current 
and former substance users.  In humans, opiate addicts are more impulsive than non-
                                                 
2 This work was published in the Archives of General Psychiatry (Love et al., 2009) in collaboration with 
Dr. Jon-Kar Zubieta at the University of Michigan and Dr. Christian Stohler at the University of Maryland. 
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addicts as measured by an increase in the discounting of delayed rewards (i.e. the 
devaluation of rewards as a function of time) (Madden et al., 1997)  and by a reduction in 
reflection (i.e. the tendency to use information when making a decision) (Clark et al., 
2006). In animals, it has been shown that in rodents a preference for immediate reward 
over larger, delayed reward predicted the development of nicotine self-administration and 
maintenance of use (Diergaarde et al., 2008), suggesting that this is a trait that 
predisposes to drug dependence. This form of impulsive choice in rats has also been 
demonstrated to predict cocaine self-administration (Perry et al., 2008).  Other clinical 
populations are also characterized by or associated with impulsive behavior such as 
Attention-Deficit Hyperactivity Disorder (ADHD), Borderline Personality Disorder, 
eating disorders and pathological gambling (e.g. ADHD, (Swanson et al., 1998); 
Borderline Personality, (American Psychiatric Association, 2000); Eating Disorders, 
(Fahy and Eisler, 1993);  gambling, (Alessi and Petry, 2003)).  Whether impulsivity 
represents a predisposing factor or is at least partially the result of prior exposure to drugs 
or ongoing disease is a matter of current debate.  
Impulsive characteristics probably do not affect behavior in isolation but are also 
likely to interact with other factors such as stress.  Stressors have a negative impact on 
drug initiation, maintenance, craving and relapse (see review (Sinha, 2001)). High 
impulsive gamblers also show neuroendocrine stress axis and cardiovascular responses to 
gambling situations relative to their low impulsive counterparts (Krueger et al., 2005). In 
addition, stressors, particularly when combined with substance abuse, are thought to be 
modulated by individual impulsivity traits to increase the risk of completed suicides 
(Mann et al., 1999), particularly in younger individuals (Zouk et al., 2006).  
40 
While it is increasingly clear that impulsivity, and stress responses confer 
vulnerability to substance abuse and other risky behaviors, the neurobiological processes 
underlying these effects are still poorly understood, particularly in humans. DA 
mechanisms appear involved, for instance, utilizing another animal of impulsivity that 
utilizes anticipatory responses to a food reward as proxy, Dalley and colleagues observed 
rats demonstrating greater impulsivity prior to drug exposure exhibited lower dopamine 
(DA) D2/D3 receptor concentrations in the nucleus accumbens, increased escalation and 
maintenance of drug self-administration relative to their lower impulsivity counterparts 
(Dalley et al., 2007). Though DA function in the ventral basal ganglia is thought to have 
an important role (Thierry et al., 1976; Rouge-Pont et al., 1993; Rouge-Pont et al., 1998) 
it is unlikely to take place in isolation. The nucleus accumbens lies at the interface of 
sensorimotor and limbic systems, and through its connections with the ventral pallidum 
and the amygdala, forms part of a circuit involved in the integration of cognitive, 
affective and motor responses in animal models (Mogenson and Yang, 1991; Kalivas et 
al., 1999). This pathway and interconnected regions (e.g., insular and prefrontal cortex, 
medial thalamus) are heavily modulated by the endogenous opioid system and µ-opioid 
receptors. For example, this neurotransmitter system is recruited when drug-induced DA 
release takes place in the context of environmental novelty and stressors (Badiani et al., 
1998, 1999; Napier and Mitrovic, 1999; Day et al., 2001; Uslaner et al., 2001). Further, 
the motivated pursuit and positive behavioral responses to rewards (Pecina and Berridge, 
2005; Smith and Berridge, 2007) are enhanced by the selective administration of µ-opioid 
receptor agonists in the nucleus accumbens and ventral pallidum, nuclei that are central to 
the regulation of motivated behavior. 
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The present report examined two orthogonal behavioral traits, impulsiveness 
(IMP) and deliberation (DLB), as defined by the NEO Personality Inventory Revised 
(NEO PI-R) (Costa et al., 1992) as a function of in vivo measures of µ-opioid receptor 
neurotransmission in humans. As defined by the NEO PI-R, the IMP dimension refers to 
the tendency to act without careful consideration for consequences of delayed 
gratification, and maps on to urgency, which appears related to problem behaviors such 
as drug use (Smith et al., 2007). DLB, which corresponds to the lack of planning 
dimension, is thought to act as a moderating, opposing trait (Fisher and Smith, 2004). 
We used positron emission tomography (PET) and the µ-opioid selective 
radiotracer [11C]carfentanil at rest and during the experience of a physical and emotional 
stressor, moderate levels of sustained pain. Under these experimental conditions, 
reductions in the availability of µ-opioid receptors during the stress challenge reflect the 
activation of endogenous opioid neurotransmission and µ-opioid receptors (Zubieta et al., 
2001). It was hypothesized that individual levels of IMP and DBL would be positively 
and negatively associated, respectively, with the functional response of the µ-opioid 
system during the stressor. Furthermore, that these effects would take place in 
motivational circuits modulated by this neurotransmitter system, namely the rostral 
anterior cingulate and adjacent medial prefrontal cortex, nucleus accumbens/ventral 
pallidum, medial thalamus and amygdala.   
 
Materials and Methods 
Subjects 
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Nineteen (19) healthy right-handed, non-smoking men (age range 20-30 years; 
(mean ± SD, 23 ± 3 years) were recruited via advertisement. In addition to completing 
physical and neurological examinations, subjects were screened using the Structured 
Clinical Interview for DSM-IV (non-patient version, SCID-NP). Subjects had no current 
or past history of medical, neurological, or psychiatric illnesses, including substance 
abuse or dependence and alcohol intake less than 5 drinks/week. Participants reported no 
current or recent (within 6 months) history of exposure to centrally active prescription or 
illicit drugs and were asked to restrain from any alcohol intake for 48 hours prior to 
scanning. Urine drug screens were performed immediately prior to imaging. Subjects 
reported no family history of psychiatric disease in first-degree relatives. The sample was 
restricted to males due to the known sex differences in the regional concentration of µ-
opioid receptors (Zubieta et al., 1999), and in the activity of this neurotransmitter system 
in response to stress (Zubieta et al., 2002), an effect that is influenced by circulating 
gonadal steroids (Smith et al., 2006). Furthermore, a link between impulsivity and 
substance use disorders has been shown most conclusively in males (see Discussion). 
Protocols were approved by the Investigational Review Boards of the Universities 
of Michigan and Maryland and the Radioactive Drug Research Committee at the 
University of Michigan. Written informed consent was obtained in all subjects. 
 
Personality Inventories 
Subjects were administered the NEO Personality Inventory Revised (NEO PI-R) 
(Costa et al., 1992). The facets “Impulsiveness” (IMP), defined as “a lack of control over 
cravings or desires”, and “Deliberation” (DLB), or the “tendency to think carefully before 
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acting”, were utilized as the primary scales of interest.  These facets have been previously 
demonstrated to reflect the dimensions of impulsivity that have been associated with 
negative risk taking (Fischer et al., 2004; Smith et al., 2007).  Individuals endorsing 
greater behavioral under-control or lack of reflection would display higher IMP and 
lower DLB scores. The median scores in population samples of comparable age were 
utilized to separate the study sample into high and low scoring groups (population data, 
IMP, mean ± SD, 15 ± 4; DLB, mean ± SD, 18 ± 4 (Costa et al., 1992). Study sample 
data, IMP, mean ± SD, 15 ± 3; DLB, mean ± SD, 18 ± 3 (Median = 15, High, n = 9 
subjects, Low, n = 10; DLB: median = 18, High, n = 9, Low, n = 10). 
 
Stress Challenge 
We employed a physical and emotional stressor, moderate levels of sustained pain 
of experientially adjusted intensity, to activate endogenous opioid-µ-opioid mediated 
neurotransmission, as previously described (Zubieta et al., 2001; Zubieta et al., 2003). In 
short, a steady state of moderate muscle pain was maintained 45-65 min after the 
radiotracer administration by a computer-controlled delivery system through the infusion 
of medication-grade hypertonic saline (5%) into the left masseter muscle. In this model of 
sustained deep somatic pain, the intensity of the painful stimulus is standardized across 
subjects, as described in detail previously (Zhang et al., 1993; Stohler and Kowalski, 
1999). Pain intensity was rated every 15 sec from 0 (no pain) to 100 (most intense pain 
imaginable). During the baseline control condition, no infusions took place and the 
subject was instructed to lie quietly in the scanner. The pain intensity ratings obtained 
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every 15 sec were recorded in the computer controller and averaged for statistical 
analyses. 
Integrative measures of the pain experience (sensory and pain affect components) 
were obtained using the McGill pain questionnaire (MPQ), administered upon 
completion of the challenge (Melzack and Torgerson, 1971). The Positive and Negative 
Affectivity Scale (PANAS) (Watson et al., 1988), assessing the internal affective state of 
the volunteers, was obtained before and after the challenge. The infusion volume required 
for pain maintenance was also recorded and provided a measure of sustained pain 
sensitivity for the individual subject. 
 
Scanning Protocols 
Two PET scans per subject were acquired with a Siemens HR+ scanner 
(Knoxville, KN) in 3-D mode (reconstructed FWHM resolution (5.5 mm in-plane and 5.0 
mm axially), one at baseline and another using the stress challenge. Radiotracer synthesis 
and image acquisition, co-registration and reconstruction protocols were identical to 
those used in previous publications (Zubieta et al., 2001; Zubieta et al., 2002; Zubieta et 
al., 2003) . 
The total activity of [11C]carfentanil administered to each subject in each scan 
was 14.5 ± 2.7 mCi (535.0 ± 100.9 MBq), with an average mass injected of 0.02 ± 0.01 
µg/kg, ensuring that the compound was administered in tracer quantities, i.e., sub-
pharmacological doses. Fifty (50) percent of the [11C]carfentanil dose was administered 
as a bolus with the remainder delivered as a continuous infusion by a computer-
controlled automated pump to more rapidly achieve steady-state tracer levels. 
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Dynamic image data for each of the receptor scans were transformed, on a voxel-
by-voxel basis, into two sets of parametric maps, coregistered to each other: (1) a tracer 
transport measure (K1 ratio), proportional to regional cerebral blood flow, and (2) a 
receptor-related measure, distribution volume ratio at equilibrium. To avoid the need for 
arterial blood sampling, these parametric images were calculated using a modified Logan 
graphical analysis (Logan et al., 1996), using the occipital cortex (an area devoid of µ-
opioid receptors) as the reference region. The Logan plot became linear by 5-7 minutes 
after the start of radiotracer administration, with a slope proportional to the (Bmax/Kd)+1 
for this receptor site. Bmax/Kd is the “receptor related” measure (µ-opioid receptor 
availability or µ-opioid receptor “binding potential”, BPND) (Bmax = receptor 
concentration; Kd = receptor affinity for the radiotracer). 
MRI scans were acquired on a 1.5 Tesla scanner (Signa, General Electric, 
Milwaukee, WI) for anatomical localization and coregistration to standardized 
stereotactic coordinates. Acquisition sequences were axial spoiled gradient-recalled 
(SPGR) MR [echo time (TE)= 5.5; repetition time (TR)= 14; inversion time (TI)= 300; 
flip angle= 20o; number of excitations (NEX)= 1; 124 contiguous images; 1.5 mm-thick; 
24 cm field-of-view; image matrix= 256 x 256 pixels, pixel size= 0.94 mm). T1-weighted 
MR and PET images of each subject were then co-registered to each other using a mutual 
information algorithm as previously described (Zubieta et al., 2001; Zubieta et al., 2003). 
 
Image Analyses 
Differences between groups (high IMP / low IMP; low DLB / high DLB, two tail, 
unpaired t tests) were mapped into stereotactic space using z maps of statistical 
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significance with a modified version of SPM99 (Welcome Department of Cognitive 
Neurology, University College, London) and Matlab software (MathWorks, Natick, MA), 
using a general linear model. No global normalization was applied to the data, and 
therefore the calculations presented are based on absolute Bmax/Kd estimates. Only 
regions with specific µ-opioid receptor binding were included in the analyses (voxels 
with BPND values > 0.2 as calculated with SPM). A priori hypothesized regions were 
deemed significant at p < 0.0001 uncorrected for multiple comparisons. For other 
regions, significant differences were detected using a statistical threshold that controls for 
a Type-I error rate at p = 0.05 for multiple comparisons (Friston et al., 1994).  Numerical 
values for each region were obtained by averaging the values of voxels contained in each 
significant cluster, up to a p = 0.001. These data were extracted for quantification of 
regional changes in BP, graphing, determination of correlation coefficients (Pearson 
correlations at p < 0.05), rule out the presence of outliers, and further statistical analyses 




With the use of the adaptive, experientially-adjusted stimulus delivery system 
employed, producing comparable perceptions of the pain stressor among participants by 
individually titrating the rate of infusion of the algesic substance, no significant group 
differences were obtained in psychophysical measures of pain or affective state during 
the stress challenge (high vs. low IMP, high vs. low DLB) (Table 1). As would be 
expected, IMP and DLB scores were negatively correlated (r = -0.55, p = 0.015).  
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Average VAS Intensity 32 ± 16 29 ± 12 0.60 
MPQ Total 21.7 ± 8.4  20.4 ± 3.1 0.66 
PANAS Positive Affect 16.9 ± 10.1 16.2 ± 9.2 0.90 
PANAS Negative Affect 2.6 ± 3.5 3.3 ± 2.9 0.60 
Total Volume 0 to 20 2653.56 ± 1567.68 3296.35 ± 878.46 0.28 






Average VAS Intensity 34 ± 13 26 ± 13 0.20 
MPQ Total 23.3 ± 6.41 18.4 ± 4.61 0.08 
PANAS Positive Affect 18.8 ± 10.6 14.0 ± 7.6 0.30 
PANAS Negative Affect 2.7 ± 3.3 3.2 ± 3.2 0.70 
Total Volume 0 to 20 2531.50 ± 1531.91 3503.40 ± 609.10 0.09 
 
Table 1 Psychophysical Measures by Trait Data are expressed as mean ± SD. †Calculated using 2-sample 
t tests for differences between high and low IMP and DLB. 
 
Baseline µ-Opioid Receptor BP 
Impulsiveness 
Significant differences in baseline µ-opioid receptor BPND were observed between 
high and low IMP groups. Specifically, greater regional µ-opioid receptor BPND was 
observed in the high, compared to low IMP subjects, in the right anterior cingulate and 
adjacent medial frontal cortex, right ventral basal ganglia (nucleus accumbens, extending 
into ventral pallidum), and the basolateral area of the right amygdala (Table 2, Figure 2). 
No effects were obtained in the opposite direction. 
Significant positive correlations were obtained between µ-opioid receptor BPND 
and IMP scores within all these clusters (right dorsal anterior cingulate, r = 0.59, p < 





Subjects with high DLB scores showed significantly lower baseline regional µ-
opioid receptor BPND compared to the low DLB group in the right dorsolateral prefrontal 
cortex, right dorsal anterior cingulate and medial frontal gyrus, left ventral basal ganglia, 
right thalamus extending inferiorly into hypothalamus and in the right basolateral 
amygdala (Table 2, Figure 2). No effects were observed in the opposite direction. 
Significant negative correlations between µ-opioid receptor BPND and DLB scores 
were noted within the right prefrontal cortex (r = - 0.65, p = 0.003), right anterior 
cingulate (two peaks, x,y,z, coordinates in mm, 16, 10, 39, r = - 0.56, p = 0.01;  x, y, z, 8, 
14, 26, r = - 0.46, p < 0.05), and right amygdala (r = - 0.54, p = 0.02).  
49 
 
Table 2  Differences in Baseline Regional μ-Opioid Receptor BP  
Region 
Coordinates 
(x, y, z)† Cluster Size‡ Z 
High Impulsiveness > Low Impulsiveness 
Right Anterior Cingulate/Medial Frontal Cortex * 15, 3, 47 1294 4.37 
Right Ventral Basal Ganglia extending into 
Ventral Pallidum 
7, -3, -3 2660 5.85 
Right Basolateral Amygdala 31, -2, -23 440 3.70 
    
Low Deliberation > High Deliberation    
Right Prefrontal Cortex 46, 7, 52 2676 4.84 
Right Anterior Cingulate/Medial Frontal Cortex * 16, 10, 39 1294 4.02 
Right Thalamus* 12, -9, 7 3218 4.19 
Right Ventral Basal Ganglia/Hypothalamus 6, -3, -4 222 5.45 
Left Ventral Basal Ganglia -4, 5, -14 1361 4.18 
Right Amygdala 28, 0, -26 416 4.56 
 
Table 2  Differences in Baseline Regional μ-Opioid Receptor BP  † Indicates Montreal Neurological 
Institute coordinates, for significant peaks.  ‡ Cluster size is expressed in mm3. *Multiple peaks were 




Figure 2 Association between impulsiveness (IMP) and deliberation (DLB) scores and baseline µ-
opioid receptor availability. A, Areas in which significant differences in µ-receptor availability in vivo 
were observed between individuals with high and low IMP scores (left) and DLB scores (right). B and C, 
Correlations between µ-receptor nondisplaceable binding potential (BPND) and IMP and DLB scores for the 
cluster centered in the right amygdala.  
 
Stress  – Induced Activation of µ-Opioid Neurotransmission 
Impulsiveness 
 Subjects with higher IMP scores demonstrated significantly greater stress-induced 
activation of µ-opioid mediated neurotransmission, compared to subjects in the low IMP 
group, in the left orbitofrontal cortex, right dorsal anterior cingulate, ventral basal 
ganglia, bilaterally, extending into the hypothalamus, left anterior thalamus and 
basolateral amygdala bilaterally. (Table 3, Figure 3). There were no regions where the 
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high IMP group showed significantly lower stress-induced changes in µ-opioid receptor 
BPND relative to the low IMP group. 
Significant positive correlations between µ-opioid system activation (baseline 
BPND – pain BPND) and IMP scores were noted in the left orbitofrontal cortex (r = 0.63, p 
< 0.005), right ventral basal ganglia (r = 0.49, p = 0.03), left anterior thalamus (r = 0.61, p 
= 0.006), and right amygdala (r = 0.50, p < 0.03).  
 
Deliberation 
Significant differences in stress-induced activation of endogenous opioid 
neurotransmission were also detected between the high DLB and low DLB groups. 
Opposite to the high IMP group and in a direction similar to that observed for baseline 
binding measures, the high DLB group showed lower stress-induced activation of the 
endogenous opioid system compared to the low DLB group in a number of brain regions. 
These included the left dorsolateral prefrontal cortex, right anterior cingulate/medial 
frontal cortex, orbitofrontal cortex bilaterally, ventral basal ganglia, bilaterally, with 
extension into the anterior hypothalamus, and basolateral amygdala bilaterally. No effects 
were obtained in the opposite direction (Table 3, Figure 3). 
Significant negative correlations between µ-opioid system activation and DLB 
scores were observed within the left dorsolateral prefrontal cortex (r = - 0.69, p = 0.001), 
right anterior cingulate (r = - 0.61, p = 0.005), right and left ventral basal ganglia (r = - 
0.54, p < 0.02 and r = - 0.60, p < 0.01, respectively), and right amygdala (r = - 0.70, p =  
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0.001).  The left amygdala cluster followed a similar pattern at trend levels of correlation 
(r = - 0.41, p = 0.08).
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Table 3  Differences in Stress-Induced Changes in Regional μ-Opioid Receptor BP  
    Baseline BP Pain BP % Change 
Region 
Coordinates 

















High IMP (Baseline-Pain) > Low IMP (Baseline-Pain) 
L Orbitofrontal Cortex -13, 29, -25 434 3.87 0.87 ± 0.32 0.76 ± 0.21 0.62 ± 0.17 0.82 ± 0.19 -33.4% 7.3% 
R Anterior Cingulate 15, 2, 47 661 4.59 0.76 ± 0.29 0.41 ± 0.13 0.55 ± 0.18 0.53 ± 0.13 -32.0% 24.5% 
L Thalamus  -10, 0, 5 629 3.98 1.10 ± 0.22 1.02 ± 0.10 0.98 ± 0.17 1.24 ± 0.20 -11.9% 18.9% 
R Ventral Basal Ganglia 
extending into Diencephalon* 6, -3, -4 2776 7.46 1.97 ± 0.47 1.54 ± 0.19 1.41 ± 0.15 1.57 ± 0.20 -33.3% 1.8% 
L Ventral Basal Ganglia -8, 15, -5 233 3.69 2.32 ± 0.34 2.06 ± 0.20 2.01 ± 0.32 2.16 ± 0.34 -14.3% 4.9% 
R Basolateral Amygdala 29, -1, -27 466 4.83 1.47 ± 0.28 1.18 ± 0.25 1.09 ± 0.24 1.19 ± 0.11 -29.5% 0.6% 
L Basolateral Amygdala -20, 3, -30 337 5.61 1.16 ± 0.35 0.86 ± 0.27 0.86 ± 0.22 0.97 ± 0.24 -29.4% 12.1% 
Low DLB (Baseline-Pain) > High DLB (Baseline-Pain) 
B Orbitofrontal Cortex* -7, 34, -26 2206 3.73 0.69 ± 0.21 0.88 ± 0.13 0.83 ± 0.09 0.66 ± 0.09 18.5% -27.7% 
L Prefrontal Cortex -33, 7, 38  2266 3.90 0.42 ± 0.12 0.59 ± 0.22 0.59 ± 0.15 0.44 ± 0.13 34.1% -30.0% 
R Anterior Cingulate 16, 10, 39 3596 4.48 0.54 ± 0.09 0.76 ± 0.18 0.63 ± 0.12 0.56 ± 0.14 25.8% -44.2% 
R Ventral Basal Ganglia 
extending into Diencephalon* 6, -3, -4 2449 4.64 1.25 ± 0.11 1.57 ± 0.23 1.41 ± 0.15 1.26 ± 0.11 12.0% -22.0% 
L Ventral Basal Ganglia -2, 4, -15 578 4.57 0.84 ± 0.27 1.15 ± 0.24 1.03 ± 0.25 0.85 ± 0.28 19.9% -29.0% 
R Basolateral Amygdala 28, 0, -26 599 4.40 1.21 ± 0.18 1.55 ± 0.39 1.30 ± 0.11 1.17 ± 0.23 7.0% -28.3% 
L Basolateral Amygdala -21, 6, -30 145 4.61 0.86 ± 0.19 1.03 ± 0.36 1.12 ± 0.26 0.74 ± 0.19 26.4% -32.9% 
Table 3  Differences in Stress-Induced Changes in Regional μ-Opioid Receptor BP Data are shown as the mean ± S.D. † Coordinates (x,y,z) refer to ICBM 
coordinates, in mm. ‡ Cluster size is expressed in mm3. *Multiple peaks detected in this region. Diencephalic regions included thalamus and hypothalamus. % 




Figure 3. Association between impulsiveness (IMP) and deliberation (DLB) scores and stress-induced 
activation of µ-opioid receptor (µ-receptor)–mediated neurotransmission. A, Areas in which 
significant differences in endogenous opioid activity during stress were observed between individuals with 
high and low IMP scores (left) and DLB scores (right). B and C, Correlations between opioid system 
activation and IMP and DLB scores for the cluster centered in the right amygdala. BPND indicates 
nondisplaceable binding potential. 
 
Interactions Among Measures: Conjunction Analyses 
The above data suggested the presence of some, but not complete regional overlap 
for the effects of the related traits IMP and DLB, with neurochemical findings in opposite 
directions, as would be expected for opposing traits. In an additional analysis, we sought 
to determine how the individual combination of these two behavioral traits segregated at 
the levels of anatomical and neurochemical substrates (µ-opioid receptor availability and 
neurotransmitter responses to stress). Individuals were divided into “behavioral risk” 
groups based on their IMP and DLB classifications, resulting in three groups with 
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relatively high (High IMP/Low DLB, n=7), low (Low IMP/High DLB, n=7) or 
intermediate (High IMP/High DLB, Low IMP/Low DLB, n=5) behavioral trait 
vulnerability.  Intermediate groups were not separated because of the small sample sizes 
in those cells. Then, for both the baseline and activation conditions, we identified brain 
areas of coincidence, where BPND and stress-induced release were greater in both the 
high IMP and low DLB groups.  For this purpose, the ImCalc function within SPM was 
utilized to generate a “mask” that contained only those voxels that were significantly 
different above a p =0.007 (T=1.99) in both of the contrasts (Contrast1 = High vs. Low 
IMP, Contrast 2 = Low vs. High IMP; Formula:  [(Contrast 1 T score > 1.99)*(Contrast 2 
T score > 1.99)].  The resulting area of coincidence contained voxels that were 
independently significant in each and both of the contrasts, whose joint probability is 
given by multiplying the probabilities for each contrast: 0.007 x 0.007 = p ≤ 0.000049 
(e.g. (Dolcos et al., 2004)). Measurement values for the regions identified were then 




Three regions showed significant overlap among the two traits: right anterior 
cingulate, right ventral pallidum, and right amygdala. The baseline BPND for each of the 
regions analyzed increased in a stepwise progression from the group with the lowest 
vulnerability traits (Low IMP/High DLB) to the highest (High IMP/Low DLB) (Figure 4, 
Table 4).  This effect was tested statistically with ANOVA, which showed significant 
effects of “risk” classification for each of the regions ([right anterior cingulate (F(2,16) = 
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8.009, p = 0.004), right nucleus accumbens/ventral pallidum (F(2,16) = 8.157, p=0.004), 
right amygdala (F(2,16) = 5.280, p = 0.017)]). Post-hoc tests (Tukey HSD) are shown in 
Table 4. Of note, both intermediate groups High IMP/High DLB and Low IMP/Low 
DLB showed similar results for these regions (data not shown).  
 
Stress –Induced Activation of µ-Opioid Neurotransmission 
Five regions showed significant activation overlap among traits: right anterior 
cingulate, right and left nucleus accumbens/ventral pallidum, and right and left amygdala. 
Again, we observed a stepwise progression in stress-induced endogenous opioid system 
activation, with the smallest change in the group with the fewest vulnerable behavioral 
traits (Low IMP/High DLB) and the greatest from the group with the most (High 
IMP/Low DLB) (Figure 4, Table 4).  A significant main effect of group on stress-induced 
activation of µ-opioid neurotransmission was present for each of the regions ([right 
anterior cingulate (F(2,16) = 10.53, p=0.001), right ventral pallidum (F(2,16) = 40.91, 
p<0.0001), left ventral pallidum (F(2,16) = 5.10, p=0.019), right amygdala (F(2,16) = 
23.54, p <0.001), left amygdala (F(2,16) = 5.05, p=0.020)]). Post-hoc tests results are 
shown in Table 4. As with the baseline data, intermediate groups showed similar results 




Table 4  Conjunction Analyses  
 
Baseline 









R Anterior Cingulate 0.87 ± 0.09 0.63 ± 0.12 0.50 ± 0.05  
R Ventral Basal Ganglia extending 
into Diencephalon* 1.76 ± 0.11 1.54 ± 0.11 1.29 ± 0.08  
R Basolateral Amygdala 1.58 ± 0.14 1.52 ± 0.11 1.13 ± 0.06  
     
Stress-Induced Changes 
















L Orbitofrontal Cortex* 0.98 ± 0.12 0.75 ± 0.06 0.92 ± 0.05 0.67 ± 0.07 0.70 ± 0.07 0.92 ± 0.04 
R Anterior Cingulate 0.79 ± 0.09 0.53 ± 0.07 0.43 ± 0.05 0.53 ± 0.07 0.51 ± 0.07 0.56 ± 0.05 
R Ventral Basal Ganglia extending 
into Diencephalon* 1.42 ± 0.05 1.32 ± 0.06 1.20 ± 0.06 1.06 ± 0.04 1.31 ± 0.04 1.28 ± 0.07 
L Ventral Basal Ganglia 2.26 ± 0.13 2.04 ± 0.09 1.94 ± 0.08 1.88 ± 0.13 2.03 ± 0.16 2.09 ± 0.10 
R Basolateral Amygdala 1.33 ± 0.09 1.31 ± 0.10 1.08 ± 0.04 0.97 ± 0.06 1.14 ± 0.05 1.14 ± 0.02 
L Basolateral Amygdala 1.75 ± 0.11 1.66 ± 0.28 1.69 ± 0.08 1.51 ± 0.12 1.65 ± 0.22 1.90 ± 0.16 
 
Table 4 Conjunction Analyses Data are shown as the mean ± S.E.M. † Coordinates (x,y,z) refer to ICBM coordinates, in mm. ‡ Cluster size is expressed in 
mm3. *Multiple peaks detected in this region. Coordinates indicate center of largest peak. Diencephalic regions included thalamus and hypothalamus. % 
Change represents the mean percent change in regional μ-opioid receptor binding potential between baseline and stress conditions. R = right, L = left. IMP = 





Figure 4  Conjunction analysis of impulsiveness (IMP) and deliberation (DLB) effects on µ-opioid 
receptor BPND and stress-induced endogenous opioid system activity.  A, The µ-receptor BPND for high 
(high IMP/low DLB), intermediate (low IMP/low DLB or high IMP/high DLB), and low (low IMP/high 
DLB) behavioral risk groups in the amygdala. *P<0.05.  Bars indicate mean values; error bars, standard 
error of the mean. B, Areas with color overlap show coincidence regions for IMP and DLB effects on µ-
receptor BPND. The amygdala (the baseline µ-opioid BPND that is shown in A) is highlighted by the yellow 
square. C, Stress-induced µ-opioid system activation for high, intermediate, and low behavioral risk groups 
in the amygdala. *P <0.05. D, Areas with color overlap show coincidence regions for IMP and DLB effects 
on stress-induced µ-opioid system activation.  The amygdala (the stress-induced µ-opioid system activation 
that is shown in C) is highlighted by the yellow square. 
 
Discussion 
The present study demonstrates that impulsiveness and deliberation are highly 
predicted by measures of endogenous opioid function in limbic regions. The personality 
facets studied here refer to the tendency to act rashly and without forethought, and have 
been associated with various psychopathologies and risky phenotypes (e.g., drug 
consumption, pathological gambling, personality disorders) (American Psychiatric 
Association, 2000; Alessi and Petry, 2003; Fischer et al., 2004; Smith et al., 2007).  Our 
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major findings are threefold:  First, we find that individuals displaying these risky 
phenotypes (e.g. high IMP or low DBL) have higher µ-opioid receptor BPND at rest 
within regions implicated in decision making, reward seeking and emotional responsivity.  
This higher BPND reflects a greater availability of µ-opioid receptors in a high affinity 
state (e.g., binding to an agonist radiotracer at low, tracer concentrations) (Narendran et 
al., 2004). Second, following a pain stress challenge we find larger reductions in BPND 
from baseline in individuals displaying high IMP/low DLB in overlapping regions. These 
reductions reflect processes related to the release of endogenous opioid interacting with 
µ-opioid receptors, so these receptors are no longer available for binding to the 
radioligand (Innis et al., 1992; Narendran et al., 2004). Third, we demonstrate a 
cumulative effect of personality traits on in vivo measures of µ-opioid neurotransmission.  
We found that individuals exhibiting extreme traits (high IMP/low DLB and low 
IMP/high DLB) display the greatest and smallest, respectively, baseline µ-opioid receptor 
availability and endogenous opioid system responses to the pain stressor employed. 
Personality traits, like impulsiveness, likely manifest as a result of a variety of 
factors, both biological and genetic. Converging lines of evidence indicate the opioid 
system as one candidate system involved in the expression of the non-planning dimension 
of impulsiveness described here.  Previous research on a measure related to the non-
planning dimension of impulsiveness, delayed discounting, which refers to the 
devaluation of rewards as a function of time, has indicated prominent roles for several 
neurotransmitters: serotonin (e.g.  (Winstanley et al., 2005)), dopamine (e.g.  (Winstanley 
et al., 2005)) and based upon the present results, opioids.  Manipulation of the opioid 
system affects preferences for immediate rewards; for instance, and in animal models, 
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Kieres and colleagues demonstrated that morphine could increase the rate of delayed 
discounting among rats, an effect blocked by naloxone (Kieres et al., 2004). Few human 
studies have directly addressed this issue, however, multiple studies have shown that 
several psychiatric groups show steeper discounting of delayed rewards such as 
pathological gamblers (e.g. (Dixon et al., 2004)and drug addicts (e.g. opiate, (Madden et 
al., 1997).  In addition, opiate addicts show a greater preference to immediate monetary 
rewards relative to non-addicts (Madden et al., 1997), a preference that is potentiated 
following mild opiate deprivation (Giordano et al., 2002). 
In the present work we show that individuals displaying risky personality traits 
(high IMP, low DLB) showed significantly greater regional µ-opioid receptor availability 
at baseline and stress-induced regional µ-opioid system activation when compared to 
individuals endorsing low IMP, high DLB. These effects were observed in multiple brain 
regions including the orbitofrontal, medial prefrontal and cingulate cortex, nucleus 
accumbens/ventral pallidum and amygdala.  Individually, these regions are known to be 
involved in impulsive choice, reward seeking, and cognitive-emotional integration and 
are heavily modulated by µ-opioid receptors (Khachaturian and Watson, 1982; Mansour 
et al., 1990; Vogt et al., 2001).  Many of these regions, particularly the prefrontal cortex 
and nucleus accumbens have been implicated in disorders characterized by or associated 
with impulsive behavior such as ADHD, substance abuse disorder, and pathological 
gambling (ADHD, see review (Spencer et al., 2002); Substance Abuse, see review 
(Volkow et al., 2004); Gambling, (Reuter et al., 2005)). Manipulation of nucleus 
accumbens activity can directly influence impulsive behavior, i.e., stimulation of the 
nucleus accumbens core has been shown to decrease impulsive choice (Sesia et al., 
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2008), whereas lesions increase impulsive choice (Cardinal et al., 2001).  Similar roles 
have been ascribed to the prefrontal cortex, orbitofrontal and amygdala, thought to 
contribute to decision making by the cognitive and emotional evaluation of future 
consequences (Bechara et al., 1994; Bechara et al., 1996).  Collectively, these regions are 
thought to be involved in the pursuit and receipt of natural rewards, decision-making and, 
more generally, motivated behavior (Austin and Kalivas, 1991; Napier, 1992; Hiroi and 
White, 1993; Johnson et al., 1993; Berridge, 1996; Gong et al., 1996; Napier and 
Mitrovic, 1999; Tom et al., 2007).  Neurobiologically this modulation of motivated 
behavior is thought to take place as a result of their extensive reciprocal connections, 
well-described between the nucleus accumbens, ventral pallidum, mediodorsal nucleus of 
the thalamus, prefrontal cortex and amygdala (Haber et al., 1985; Kelley et al., 2005). 
We also observed greater stress-induced activation of this neurotransmitter system 
in subjects scoring above the population average of NEO IMP scores, compared with 
subjects scoring below, in regions at least partially overlapping with those where baseline 
differences in µ-opioid receptor BPND were observed. Opposite effects (lower stress-
induced opioid system activity in high scoring subjects) were observed for the orthogonal 
domain, DLB. These data then supports the contention that there are interactions between 
neurobiological processes related to stress responsiveness and impulsivity. Physiological 
stress responses seem greater in more impulsive individuals even among risky 
populations (e.g., pathological gamblers, Krueger et al., 2005) and therefore point to 
factors that may contribute to interindividual variations in risky behavior even among 
pathological states. Outbred rats exposed to the mild stress of a novel environment may 
show high (HR) or low (LR) rates of exploratory locomotion, and HR rats learned to self-
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administer psychostimulants faster than LRs (Piazza et al., 1989; Marinelli and White, 
2000; Piazza et al., 2000; Kabbaj et al., 2001). It has been proposed that activation of DA 
neurotransmission and stress responses during risky behavior are the critical variable 
underlying the reinforcement of this behavior in the more impulsive individuals (Dellu et 
al., 1996), an effect that may be mediated by the increase in corticosterone induced by the 
stressor (Deroche et al., 1992; Deroche et al., 1993, 1994; Rouge-Pont et al., 1995). 
Relevant to the results presented here, HR rats, more prone to acquire drug-self 
administration also show increased nucleus accumbens proenkephalin gene expression 
(Lucas et al., 1998). 
A conjunction analysis more formally determined the overlap in the processes and 
brain regions where IMP and DLB effects were obtained. It demonstrated a cumulative 
effect of personality risk factors on measures of µ-opioid neurotransmission. Extreme 
traits (high IMP/low DLB, low IMP/high DLB) demonstrated greatest and smallest, 
respectively, endogenous opioid system responses to a standardized stressor and µ-opioid 
receptor availability at baseline. “Intermediate”, compounded traits (high IMP/high DLB, 
low IMP/low DLB) showed intermediate effects for both measures. This is consistent 
with the observation that the accumulation of risky traits is associated with a greater 
probability of problem behaviors and substance use problems (Bry, 1982). The 
coalescence of IMP and DLB effects were observed in the dorsal anterior cingulate, 
nucleus accumbens/ventral pallidum and amygdala, centrally implicated in decision-
making and motivated behavior, as noted above (Mogenson and Yang, 1991; Kalivas et 
al., 1999; Bush et al., 2002).  
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Regional µ-opioid receptor availability and µ-opioid system activation during the 
stressor accounted for 24 to 40% of the variance in IMP scores, and 17 to 49% of the 
variance in DBL scores. In contrast, no significant relationships have been reported 
between NEO impulsiveness and dopamine D2/3 receptor binding in the basal ganglia as 
measured with [11C]raclopride (Oswald et al., 2007) or with dopamine turnover as 
measured with [18F]fluorodopa (Laakso et al., 2003). Amphetamine-induced dopamine 
release in the ventral basal ganglia accounted for 9-20% of the variance in NEO 
impulsiveness scores in a healthy sample otherwise similar to the one studied in the 
present report (Oswald et al., 2007). 
Because the study sample was restricted to males to reduce experimental 
complexity, additional questions remain that will need to be addressed in subsequent 
work. Effects of gender, gonadal steroids and age by gender interactions have been 
described for the µ-opioid receptors and stress-induced µ-opioid system activation 
(Zubieta et al., 1999; Zubieta et al., 2002; Smith et al., 2006). These effects may or may 
not be related to IMP and DBL traits and will require specific studies addressing their 
effects. From a different perspective, impulsive behavior has been suggested to be a 
result of prefrontal cortex dysfunction.  For instance, Bechara and others reported 
problems with decision making, specifically insensitivity to future consequences, 
following damage to the ventromedial prefrontal cortex (Bechara et al., 1994; Bechara et 
al., 1996). The relationship between ventral prefrontal cortex function and endogenous 
opioid system activity measures are presently unexplored. 
It is also unlikely that complex personality domains are solely related to a single 
neurotransmitter system. Indeed, DA D2/3 receptor concentration within the ventral basal 
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ganglia has been demonstrated to predict impulsive anticipatory responses to food reward 
in an animal model of impulsivity (Dalley et al., 2007) .  The involvement of 
dopaminergic mechanisms, however, is not exclusionary of the involvement of other 
systems, such as the endogenous opioid. DA-opioid interactions have been described in 
the striatopallidal pathway and interconnected regions, where acute and chronic DA 
receptor stimulation induce opposite effects on the functional capacity of the µ-opioid 
system in animal models (George and Kertesz, 1987; Unterwald et al., 1989; Unterwald 
et al., 1992; Chen et al., 1993; Unterwald et al., 1994; Steiner and Gerfen, 1998) and in 
humans (Zubieta et al., 1996; Zubieta et al., 2003).  These and other, not yet described 
neurotransmitter systems may underlie the psychophysical differences, such as heart rate 
and pupilary responses, classically noted between otherwise healthy shy and uninhibited 
children (Kagan et al., 1988). 
The present study provides the first evidence in humans that IMP and DBL, 
behavioral facets relevant to motivated behavior, the pursuit of reward and risk taking, 
including the development of substance use disorders, are related to the individual 
function of the endogenous opioid system. Baseline measures of µ-opioid receptor 
availability and the capacity to activate this neurotransmitter system in limbic and 
paralimbic regions accounted for up to half of the variance in trait IMP and DBL scores 




Sex-Environment Interaction in the Dopaminergic Response to a Pain Stressor3 
 
 
There is considerable variation in how a given individual responds to stress.  The 
factors which influence stress-responsiveness are still being uncovered, however, some 
evidence suggests that life experiences, like previous exposure to stressful environmental 
situations, and gender can alter acute stress responses.  For example, a recent meta-
analysis indicated that exposure to life stress is generally associated with poorer recovery 
of cardiovascular reactions following an acute stressor (Chida and Hamer, 2008).  In 
addition, high levels of life stress can also induce reductions in immunological reactivity 
to an acute stressor (e.g. (Brosschot et al., 1994)).  
Much evidence suggests that, in general, women and men respond differently to 
stress.  There are well documented sex differences in the prevalence of stress-related 
disorders such as major depression, posttraumatic stress disorder, and idiopathic pain 
syndromes such as fibromyalgia and temporomandibular pain disorder (Bush et al., 1993; 
Kessler et al., 1995; Kornstein, 1997; Yunus, 2001); symptoms of which are often 
predated and exacerbated by stressful life events (e.g. (McGonagle and Kessler, 1990; 
Hammen et al., 1992; Kessler, 1997; Dancey et al., 1998; Monroe et al., 2001; Muscatell 
et al., 2009)).  In addition, rates of substance use and dependence vary between men and 
women which is also heavily moderated by stress (Sinha, 2008; SAMHSA, 2009).  
                                                 
3 This work reflects collaboration with Dr. Jon-Kar Zubieta, Dr. Robert Koeppe and Dr. Jill Becker at the 
University of Michigan and Dr. Christian Stohler at the University of Maryland. 
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Relative to men, women progress from initiation to addiction faster than men and enroll 
into treatment programs sooner (Haas and Peters, 2000; Hernandez-Avila et al., 2004; 
Becker et al., 2007)) 
Acute responses to stress can differ between men and women; in terms of 
responses to a painful stressor, men report lower pain ratings and have higher pain 
thresholds relative to women given the same stimulus (see (Fillingim, 2000).  These sex 
differences, however, have been shown to be impacted by environmental conditions, such 
as exposure to stress.  For example, in animals, exposure to repeated restraint sessions 
has been shown to reduce acute tail flick latency in male but not female rats (Gamaro et 
al., 1998). In humans, exposure to sedentary competitive stress prior to cold pressor stress 
produces analgesia in men but not women (Sternberg et al., 2001).  The biological origins 
of such sex-specific differences have just begun to be revealed but it appears that at the 
neurochemical interface of stress and sex lays dopamine. 
Dopamine, well known for its role in the encoding and modulation of motivated 
behavior and reward is being increasingly recognized as a player in responses to negative 
events such as stress and pain (Thierry et al., 1976; Pruessner et al., 2004; Scott et al., 
2006).  There is great variation in dopaminergic responses to such negative stimuli and 
some evidence indicates that such responses are influenced by both biological and 
environmental conditions including sex and life stress (Pruessner et al., 2004; Scott et al., 
2006). Recent stressors in animals appear to enhance DA release from the nucleus 
accumbens and promote psychostimulant drug self-administration in animals (Piazza and 
Le Moal, 1997). Similarly, individuals experiencing early life stress express an enhanced 
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dopaminergic response within the ventral striatum in response to a psychosocial stressor 
(Pruessner et al., 2004).   
In terms of sex, in animals, intact female rats show greater DA release within the 
nucleus accumbens relative to male rats in response to ethanol (Blanchard et al., 1993) 
and ovariectomized females show enhanced amphetamine-induced DA release in the 
striatum relative to castrated males (Castner et al., 1993).  Human studies have been more 
equivocal. Greater release of DA has been shown in a small sample of healthy females in 
response to the psychostimulant amphetamine using positron emission tomography (PET) 
and the radiotracer [11C] fallypride, localized in the globus pallidus and inferior frontal 
gyrus (Riccardi et al., 2006a). Munro and collaborators however showed evidence of 
greater DA release in response to the same challenge in the ventral striatum of males, 
using PET and [11C] raclopride (Munro et al., 2006). The relatively small samples sizes 
in the female groups and lack of standardization of menstrual cycle phase may have 
contributed to this apparent discrepancy in results.  Another explanation for these 
inconsistencies is the interaction of a third uncontrolled variable on dopamine release, 
such as exposure to life stress (e.g. (Pruessner et al., 2004; Oswald et al., 2007)).   
To examine this possibility further, we examined sex differences in the 
availability of DA D2/3 receptors during a physical and emotional stressor, moderate 
levels of sustained pain. Prior to scanning, participants were asked to complete a survey, 
which detailed significant life stressors that may or may not have occurred during the last 
year. Participants were then segregated into two groups:  Recent Life Stress (RLS), which 
included individuals that reported having experienced some form of significant life stress 
in the past year, and No Recent Life Stress (NoRLS), where the participants did not detail 
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any recent life stressors. Analyses were performed to determine the impact of sex and life 
stress on dopaminergic activity measured using [11C] raclopride PET.   
Previous work from our lab has indicated that use of a non-pharmacological stress 
challenge can induce DA release in both dorsal and ventral basal ganglia regions (Scott et 
al., 2006). This study sought to extend those previous findings and determine whether sex 
differences exist in these dopaminergic responses and whether recent life events can 
make a significant impact. In view of the basic research literature reviewed above, it was 
expected that DA release would be more pronounced in women than in men during an 
otherwise comparable stressor and that exposure to recent life stress would influence this 
response. 
 
Materials and Methods 
Subjects 
Twenty-two healthy right-handed men (age mean ± SD, 25.7 ± 3.3 years) and 
twenty-two healthy right-handed women (age mean ± SD, 27.5 ± 6.1 years) were 
recruited via advertisement. In addition to complete physical and neurological 
examinations, subjects were screened using the Structured Clinical Interview for DSM-
IV (non-patient version, SCID-NP) and had no current or past history of medical, 
neurological, or psychiatric illness, including substance abuse or dependence. Subjects 
were not taking any psychotropic medications or hormone treatments, including birth 
control in women, for at least six months and were non-smokers.  Subjects did not 
exercise in excess of 1 hour three times a week nor were they involved in competitive 
exercise.  All women were studied in the follicular phase of the menstrual cycle, 
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confirmed with plasma levels of estradiol and progesterone prior to scanning.  Protocols 
were approved by the University of Michigan Investigational Review Board and the 
Subcommittee for Human Use of Radioisotopes (Ann Arbor, MI). Written informed 
consent was obtained in all subjects. 
 
Life Stressors 
All subjects completed the Health and Daily Living Form.  The indices of life 
change events section, which asks individuals to indicate which if any stressful events 
recently occurred in their lives and when was used to provide a profile of an individual’s 
life stressors over the last 12 months. We chose to focus on negative life events as these 
are more strongly associated with problem behavior (i.e. substance abuse) and impaired 
functioning (i.e. development of depressive episodes, interpersonal problems) than 
positive life changes (Sarason et al., 1978; Billings and Moos, 1981).  Typical significant 
negative life events included: divorce, death of a spouse, loss of job, etc. In this sample of 
healthy subjects the number of stressors per individual was low, not allowing for the 
number of stressful life events to be effectively considered as a variable in the analyses. 
Further detail is included in the Results section.  
 
Study Protocol 
Each subject underwent a 90 minute PET scan with [11C] raclopride, a DA 
radiotracer with affinity for both D2 and D3 receptors (Seeman et al., 2006). A portion of 
this sample was previously studied for pain-stress effects on dopaminergic activity (Scott 
et al., 2006) and details regarding study criteria have been given elsewhere (Scott et al., 
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2006). Briefly, we employed a universal physical and emotional stressor, moderate levels 
of sustained pain, which has been shown to activate DA neurotransmission in the basal 
ganglia (Scott et al., 2006). A steady state of muscle pain was maintained over 20 min 
from 45-65 min post-tracer administration. This took place through a computer-
controlled infusion of medication-grade hypertonic saline (5%) administered into the left 
masseter muscle.  Pain intensity was rated every 15 seconds from 0 (no pain) to 100 
(most intense pain imaginable) using an electronic version of 100mm visual analog scale 
(VAS). The individual ratings of pain intensity were employed by the computer 
controller to maintain constant pain in a manner comparable across subjects using a target 
of 40 VAS units, as previous described (Zhang et al., 1993; Stohler and Kowalski, 1999). 
Upon completion of the pain challenge, integrative measures of the experience were 
obtained using the McGill pain questionnaire (MPQ) (Melzack and Torgerson, 1971) and 
the Positive and Negative Affectivity Scale (PANAS) (Watson et al., 1988), the latter 
assessing the internal affective state of the participants. Preceding the pain stress 
challenge, subjects underwent a baseline control condition during which there was no 
expectation of pain and no infusions took place. 
 
Neuroimaging methods 
PET scans were acquired with a Siemens (Knoxville, TN) HR+ scanner in 3-D 
mode (reconstructed full-width at half maximum (FWHM) resolution (~5.5 mm in-plane 
and 5.0 mm axially).  Radiotracer synthesis and image acquisition, coregistration and 
reconstruction protocols were identical to those used in previous publications (e.g. (Scott 
et al., 2006)). Briefly, images were reconstructed using iterative algorithms into a 128 x 
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128 pixel matrix in a 28.8 cm diameter field of view. Attenuation correction was 
performed through a 6 min transmission scan (68Ge source) obtained before the PET 
study. Small head motions during emission scans were corrected by an automated 
computer algorithm for each subject before analysis, and the images were coregistered to 
each other with the same software (Minoshima et al., 1993). Time points were then 
decay-corrected during reconstruction of the PET data.  
The total activity of [11C] raclopride administered to each subject was 15.4 ± 1.2 
mCi. Fifty percent of the [11C] raclopride dose was administered as a bolus with the 
remainder delivered as a continuous infusion by a computer-controlled automated pump 
to more rapidly achieve steady-state tracer levels. Under these conditions, equilibrium 
conditions across kinetic compartments are achieved approximately 35 min after tracer 
administration (Carson et al., 1997). 
Twenty-eight image frames were acquired over 90 minutes with an increasing 
duration (30 seconds up to 10 minutes) and were coregistered to each other (Minoshima 
et al., 1993). Dynamic image data for each of the receptor scans were transformed, on a 
voxel-by-voxel basis, into two sets of parametric maps, coregistered to each other: (a) a 
tracer transport measure (K1 ratio), and (b) a receptor-related measure at equilibrium 
(DVeq), the latter using data obtained from 35-45 min (control) or 60–80 min (pain 
stress) after tracer administration. DVeq -1 is proportional to Bmax/Kd, or binding potential 
at equilibrium (BPeq). This measure was obtained using the ratio of brain activity to 
activity in the cerebellum (Carson et al., 1997; Watabe et al., 2000). 
MRI scans were acquired on a 3 Tesla scanner (General Electric, Milwaukee, WI) 
for anatomical localization and coregistration to standardized stereotactic coordinates.  
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Acquisition sequences were axial spoiled gradient-recalled (SPGR) [echo time (TE), 3.4 
ms; repetition time (TR), 10.5; inversion time, 200 ms; flip angle, 25°; number of 
excitations (NEX), 1; 124 contiguous images; 1.5 mm thickness].  
T1-weighted MR and PET images of each subject were then coregistered to each 
other using a mutual information algorithm as previously described (Meyer et al., 1997). 
For this purpose, K1 images (containing anatomical information similar to that of regional 
cerebral blood flow scans) were first aligned to the MR, and the transformation matrix 
applied to the co-registered DVR scans of the same series. The MR scans were then 
anatomically standardized to ICBM brain atlas stereotactic coordinates by linear and non-
linear warping, and the resulting transformation matrix applied to K1 and DVR images 
(Meyer et al., 1997; Meyer et al., 1998). The accuracy of coregistration and warping 
algorithms were confirmed for each subject individually by comparing the transformed 
MRI and PET images to each other and the ICBM atlas template. 
 
Image Analyses 
Activation of DA D2/D3 neurotransmission is detected as a reduction in BPeq 
(i.e. lower levels of in vivo DA D2/3 receptor availability during the challenge. This was 
calculated as the difference between the control state and the activated, pain stress state. 
Differences between groups for DA activation were mapped into stereotactic space using 
F maps of statistical significance with SPM2 (Welcome Department of Cognitive 
Neurology, University College, London) and Matlab software (MathWorks, Natick, MA), 
using a general linear model and correction for multiple comparisons (Friston et al., 
1995).  No global normalization was applied to the data, and therefore the calculations 
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presented are based on absolute Bmax/Kd estimates. Only regions with specific DA D2/D3 
receptor binding were included in the analyses (voxels with BPeq values > 0.2).  To 
compensate for small residual anatomic variations across subjects and to improve signal 
to noise ratios, a three-dimensional Gaussian filter (FWHM 6 mm) was applied to each 
scan. Voxels of interest were isolated for activation using effects of interest contrasts (i.e. 
Sex, RLS, Sex x RLS) in a between subjects ANOVA.  Significant differences were 
detected using a statistical threshold that controls for a Type-I error rate at p = 0.05 for 
multiple comparisons.  This was estimated using the Euler characteristic (Worsley, 1994) 
based on the number of voxels in the gray matter and image smoothness (Friston et al., 
1991), corrected for the size of the cluster under consideration (Friston et al., 1994).  
Numerical values for each region were obtained by averaging the values of voxels 
contained in each significant cluster up to a p<0.01 level. These data were extracted for 
quantification of regional changes in BP, rule out the presence of outliers, and examined 
using further statistical analyses using SPSS for Macintosh 11.0.3 (SPSS Inc., Chicago, 
IL).  To determine group differences post hoc testing was performed for each of the 
effects of interest (Female x Male, RLS x NoRLS, Female RLS x Female NoRLS,  Male 
RLS x Male NoRLS, Female NoRLS x Male NoRLS, Female RLS x Male RLS).  To 
compensate for multiple comparisons, the p value threshold used was adjusted using the 
Bonferroni method from the standard 0.05 to 0.008. 
Results 
No significant differences between sex groups were obtained in psychophysical 
measures of pain or affective state during the experientially-matched stressor (Table 5). 
Twenty-six individuals reported having at least one significant negative life event in the 
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past year (12 men, 14 women).  No significant sex differences in the number of stressors 
were noted: 2.0 ± 1.1 life stressors were reported in males and 1.6 ± 1.0 in females (two-
tailed unpaired t-tests, p=0.41). 
 





(n=22) t p 
McGill Pain Intensity 40 ± 2 42 ± 3 -0.56 0.58 
McGill Pain Unpleasantness 43 ± 2.6 43 ± 4 -0.15 0.88 
Δ PANAS Positive Affect -5.6 ± 1.2 -5.6 ± 1.3 -0.02 0.98 
Δ PANAS Negative Affect -0.4 ± 2.1 -1.0 ± 0.7 0.28 0.78 
Average VAS/Total Volume 1.55 ± 0.26 1.55 ± 0.39 -0.01 0.99 
Total Volume 5% saline (µL) 2806 ± 241 3159 ± 278 -0.96 0.34 
 
Table 5. Psychophysical Measures by Sex. Data are shown as the mean ± 1 S.E. 
 
 
Stress-Induced Activation of DA Neurotransmission 
Using an ANOVA to examine the effects of both sex and RLS, significant sex 
effects were obtained within the nucleus accumbens, bilaterally, left caudate and left 
putamen (Table 6 & Table 7).  Post-hoc testing revealed that for the individuals that did 
not report any recent life stressors, females demonstrated significantly greater stress-
induced activation of DA neurotransmission compared to males in all regions (Table 6 & 
Table 7). 
No significant effects of recent life events (presence/absence) were observed on 
regional DA activation for the entire sample.  
A significant sex by life events interaction was also noted within the left nucleus 
accumbens (Table 6 & Table 7). In this region, the presence of recent negative life events 
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was associated with significantly greater DA responses to the experimental stressor in 
























Figure 5.  Sex by RLS interaction within the left nucleus accumbens.  Above: Location of significant 
peak in Interaction contrast.  Below:  Graph depicting binding during the control condition and during the 
challenge. * Indicates significant differences between Control and Pain conditions as determined by paired 
t-tests (Male NoRLS, p<0.0001, Female NoRLS p=0.007).  **Indicates significant differences between 









Table 6  Differences in Stress-Induced Changes in Regional DA 2/3 Receptor BP  
 
   NoRLS RLS ANOVA Stats 
Region 
Coordinates 
(x, y, z)† 
Cluster 
Size‡ Male Female Male Female F p 
Sex Effects 
R Nucleus Accumbens 
extending into R  Putamen 15, 18, -6 6806 -0.08 ± 0.03 0.13 ± 0.03 -0.02 ± 0.03 0.06 ± 0.03 21.79 0.013 
L Nucleus Accumbens -11, 9, -5 846 -0.12 ± 0.02 0.10 ± 0.03 -0.03 ± 0.03  0.00 ± -0.06  23.47 0.013 
L Caudate -15, 12, 9 708 -0.07 ± 0.04 0.14 ± 0.05 -0.01 ± 0.03 0.06 ± 0.01 19.75 0.013 
L Putamen -31, 1, -2 749 -0.11 ± 0.03 0.15 ± 0.05  -0.03 ± 0.04 0.04 ± -0.03 20.79 0.013 
Sex x Stress Interaction 
L Nucleus Accumbens -11, 8, -9 1160 -0.11 ± 0.02 0.09 ± 0.02 -0.01 ± 0.03 -0.04 ± -0.08 28.83 0.015 
 
Table 6  Differences in Stress-Induced Changes in Regional DA 2/3 Receptor BP.  Data are shown as the mean ± S.E.  † Coordinates (x,y,z) refer to ICBM 
coordinates, in mm. ‡ Cluster size is expressed in mm3. * Change represents the mean difference in regional DA 2/3 binding potential between control and 





Table 7. Post Hoc Statistics – Stress-Induced Changes in Regional DA 2/3 Receptor BP  
 
Region Male x Female RLS x NoRLS 
Male NoRLS x 
Female NoRLS 
Male RLS x 
Female RLS 
Male RLS x 
NoRLS 
Female RLS x 
RLS 
Sex Effects 
R Nucleus Accumbens 
extending into R  Putamen 
0.000* 0.899 0.000* 0.067 0.172 0.098 
L Nucleus Accumbens 0.001* 0.853 0.000* 0.443 0.025 0.018 
L Caudate 0.000* 0.990 0.004* 0.048 0.283 0.100 
L Putamen 0.000* 0.853 0.000* 0.169 0.095 0.089 
Sex x Stress Interaction 
L Nucleus Accumbens --------- ----------- 0.000* 0.368 0.008* 0.001* 
 
Table 7. Post Hoc Statistics – Stress-Induced Changes in Regional DA 2/3 Receptor BP.  Data are shown as p values. *Significant following Bonferroni 





Examining men and women separately, we observed a positive relationship 
between the change in negative affect and DA response within the right nucleus 
accumbens (r=0.466, p=0.029), left caudate (r=0.537, p=0.010), and left putamen 
(r=0.452, p=0.035) in women.  In men, however, we observed a negative relationship 
between the change in negative affect and DA response within the left (r=-0.427, 
p=0.048) and right nucleus accumbens (r=-0.423, p=0.050), and left putamen (r=-0.442, 
p=0.040).  No other relationships were observed between DA responses and any other 
psychophysical measures (i.e. McGill, PANAS, Infusion). 
 
Hormonal Measures 
No relationships between estradiol, progesterone or testosterone levels and the 
degree of stress-induced DA response were noted in females or males. 
 
Discussion 
This is the first study to demonstrate sex differences in DA activity in response to 
a painful stress challenge in healthy humans.  In addition, we observed an interaction 
between sex and recent negative life events for stress-induced DA release within the left 
nucleus accumbens.  Positive relationships were found between activation of DA 
neurotransmission within dorsal and ventral striatal regions and the change in negative 




Previous investigations indicated that dopamine neurotransmission is engaged in 
response to the pain-stress challenge employed here (Scott et al., 2006). Other 
investigations examining humans have also described increased dopamine release within 
the striatum as a result of psychological stress (Pruessner et al., 2004). However, sex 
differences in such dopaminergic responsivity have only received modest attention.  
In our sample, women exhibited greater changes in dopaminergic activity within 
the caudate, putamen and ventral striatum relative to men. The enhanced activity seen 
within women relative to men may suggest that the dopamine system is more active in 
females and may be influential in their modulation of stress and pain.  This is interesting 
considering that µ-opioid system mechanisms are thought to play a greater role in 
mediating pain and stress in men than it does within women during their follicular phase 
(Zubieta et al., 2002).  We did not observe any relationships between any of the gonadal 
hormone measures and dopaminergic activity however this may be due to our exclusion 
of women in their luteal phase.  Further research is needed to determine if the sex effects 
on stress-induced dopaminergic neurotransmission are modulated by the menstrual cycle.  
We noted a significant positive relationship between negative affective state and 
stress-induced dopaminergic activity in women; conversely a negative relationship was 
observed in men.  The positive relationship between negative affective state and 
dopaminergic system activation in females is consistent with previous observations 
indicating positive correlations with emotional ratings and dopaminergic activity within 
ventral basal ganglia (Scott et al., 2006).  The negative correlation observed in the male 
sample is somewhat perplexing.  However, in this group of subjects, males tended to 
exhibit decreases in dopaminergic activity in the areas where these negative correlations 
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were observed whereas females tended to show increases (and positive correlations with 
negative affect) in these same regions.  It appears that greater stress-induced changes in 
dopaminergic activity relative to our control condition, whether positive or negative, 
were associated with greater emotional distress in both groups.  
In addition to the sex differences in stress-induced dopamine activity, we also 
observed a significant interaction between sex and RLS. We found that relative to men 
and women who did not report RLS in the past year, the exposure to RLS was associated 
with significantly greater DA responses to the experimental stressor in men but 
significantly lesser DA activation in females. The activity between the control condition 
and pain-stress condition in both RLS males and RLS females was not observed to be 
significantly different in either sex. These data seem to indicate an overall blunting of the 
dopaminergic response in men and women, albeit in different directions.  Indeed, 
previous reports have indicated exposure to chronic stress can lead to inhibition of 
dopaminergic responses to amphetamine in humans (Oswald et al., 2007). This is 
somewhat contrary to Pruessner and colleagues work, demonstrating exaggerated 
dopaminergic responses in individuals exposed to early life stress (Pruessner et al., 2004).  
However, in predicting dopaminergic neurotransmission alterations, the nature of the 
stressor to which the individual is exposed is significant.  Though certain stressors can 
potentiate dopaminergic activity, others can lead to blunted responses (Kalivas and 
Duffy, 1989; Mangiavacchi et al., 2001; Lucas et al., 2004). Unfortunately, the measure 
utilized to determine presence of RLS in our subjects does not record how severe or 
distressing the subjects’ perceived the stress to be.  It is possible that some of the 
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differences observed could be a result of sex differences in the perception of 
controllability or severity.  Future studies will be needed to parse out these effects. 
In sum, we observe extensive dopaminergic activation differences in response to a 
painful stressor between men and women, with women showing greater dopaminergic 
responses in most regions.  We find that while sex clearly influences dopaminergic 
responses to stress, outside influences, such as the stressful life experiences, can be a 






Polymorphisms in Oxytocin Receptor Impact Dopaminergic Responses in Humans 
in a Sex Dependent Manner: a C[11] Raclopride Study4 
 
Dopamine is released in response to both psychological and physiological 
stressors (e.g. (Thierry et al., 1976; Rouge-Pont et al., 1998; Scott et al., 2006).  The 
magnitude of stress-induced dopamine release varies greatly from individual to individual 
(Scott et al., 2006).  The sources of this variability are likely many, however a portion of 
the variance is predicted to be the result of heredity.  Strain differences in the 
mesocorticolimbic dopamine response to a forced swim test have been noted in mice 
whereby the mice of a hypoactive phenotype (DBA/2) show enhanced stress-induced 
mesoaccumbal DA release relative to their more active counterpart (C57BL/6) (see 
review (Cabib et al., 2002)).  In rats, novelty-seeking phenotypes classified as high 
responders (HR) or low responders (LR) on the basis of their locomotor response to 
novelty, a mild stressor, which show differential dopamine responses in response to stress 
(Rouge-Pont et al., 1998) can be selectively bred for this trait (Stead et al., 2006).  Little 
work has been done to this end in humans, however, given dopamine’s key role in 
psychopathologies, such as addiction, schizophrenia, and depression, highlighting 
                                                 
4 This work reflects extensive collaboration with Dr. David Goldman, Dr. Mary-Anne Enoch, and Dr. Colin 
Hodgkinson at the National Institute of Alcohol Abuse and Alcoholism, Dr. Christian Stohler at the 
University of Maryland, and Dr. Jon-Kar Zubieta, Dr. Margit Burmeister and Ellen Schmidt at the 
University of Michigan. 
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potential gene targets which can impact dopaminergic responsiveness is of significant 
value. 
Recently, several groups have highlighted the important role the neuropeptide 
oxytocin plays in modulating the stress response. Oxytocin, a nonapeptide synthesized 
primarily within the hypothalamus, though first described for its ability to stimulate milk-
ejection during breastfeeding and smooth muscle contraction during labor (Dale, 1906; 
Ott and Scott, 1910), appears to have much broader effects including influencing HPA 
axis activity in response to stress.  Oxytocin is released from the pituitary into peripheral 
circulation in response to a variety of stimuli including physical stressors (e.g. Morris 
water maze (Engelmann et al., 2006), forced swimming (Lang et al., 1983; Kasting, 
1988)) and psychological stressors (e.g. shaker stress (Hashiguchi et al., 1997; Nishioka 
et al., 1998) and centrally (e.g. forced swimming (Wotjak et al., 1998),  shaker stress 
(Hashiguchi et al., 1997; Nishioka et al., 1998), osmotic stress (see (Jezova et al., 1995)).  
Multiple lines of evidence suggest oxytocin has anxiolytic and anti-stress effects, for 
instance acute intracerebral infusion of oxytocin reduces distress vocalization in rat pups 
(Insel and Winslow, 1991), increases punished crossings in the four plate test (Ring et al., 
2006) and increases time spent in the open quadrants of the elevated zero maze (Ring et 
al., 2006).  In addition, a chronic infusion of oxytocin dose dependently lowers plasma 
corticosterone concentrations following noise stress in ovariectomized female rats 
(Windle et al., 1997). Also, intracerebral infusion of oxytocin antagonist results in 
elevated stress-induced ACTH and corticosterone concentrations in both male and female 
rats (e.g. elevated plus maze (Neumann et al., 2000)).  Similarly in humans, 
administration of oxytocin intranasally also been shown to reduce cortisol responses to 
85 
 
psychosocial stressors (Heinrichs et al., 2003) and couple conflict discussions (Ditzen et 
al., 2009). 
 In addition to modulating HPA axis responsiveness, oxytocin is also capable of 
affecting central nervous system activity, including central dopaminergic functioning.  
Oxytocin and its binding sites exist in regions outside of the hypothalamus; in rats and 
primates these regions include the septum, amygdala, ventral tegmental area, nucleus 
accumbens, and various nuclei within the brainstem (primate: (Fliers et al., 1986; Caffé et 
al., 1989; Loup et al., 1991),  rat: (Brinton et al., 1984; Van Leeuwen et al., 1985; 
Krémarik et al., 1993)).  Injections of oxytocin into the ventral tegmental area, which 
contains the cell bodies of the dopaminergic neurons which makeup the core of the 
mesolimbic dopamine system, results in increases in extracellular dopamine within the 
nucleus accumbens and hypothalamus (Melis et al., 2007).  In addition, peripheral and 
intracerebral ventricular oxytocin administration can affect dopamine utilization within 
the mesencephalon (e.g. ventral tegmental area, substantia nigra), hypothalamus and 
striatum (see review (Sarnyai and Kovács, 1994)).  Oxytocin administration in rats can 
also alter central dopaminergic responses associated with a variety of behaviors, such as 
addictive behaviors (e.g. self-administration, tolerance and dependence) and stress (see 
(Kovács et al., 1984; Ibragimov et al., 1987; Sarnyai and Kovács, 1994)).   
 In sum, oxytocin is released in response to stress and is capable of affecting both 
stress and dopaminergic responsiveness.  What effect genetics has on oxytocin’s 
influence on these activities has yet to be studied.  Here, we examined genotype in 
relation to changes in healthy control subjects’ dopaminergic response to a physical and 
psychological stressor, pain, using Positron Emission Tomography (PET).  Genome wide 
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scans previously indicated several common polymorphisms near the oxytocin gene 
(Hodgkinson et al., 2008).  Blood was taken from the participants and used to genotype 
for each of the previously identified oxytocin single nucleotide polymorphisms (SNPs).  
We then examined whether these polymorphisms were associated with altered stress-
induced dopaminergic responsiveness among our participants. 
 
Materials and Methods 
Subjects 
 Thirty-two healthy right-handed women (age, mean ± SD, 26.97 ± 6.08) and 
twenty-three healthy right-handed men (age, mean ± SD, 25.74 ± 3.19) were recruited via 
advertisement. A portion of this sample was previously studied for pain-stress effects on 
dopaminergic activity and details regarding study criteria have been given elsewhere 
(Scott et al., 2006).  Briefly, subjects were screened using Structured Clinical Interview 
for DSM-IV (non-patient version, SCID-NP) and had no current or past history of 
medical, neurological, or psychiatric illness, including substance abuse or dependence. 
Subjects were not taking any psychotropic medications or hormone treatments, including 
birth control in women, for at least six months and were non-smokers.  Protocols were 
approved by the University of Michigan Investigational Review Board and the 
Subcommittee for Human Use of Radioisotopes (Ann Arbor, MI). Written informed 





DNA was extracted from blood samples taken at the time of scanning.  A 
genomic region containing sequence 5 kb upstream and 1 kb downstream of OXT, the 
oxytocin gene mapped to chromosome 20p13, was retrieved from NCBI Human Build 
35.1.  Tagging SNPs were identified using a previously described design pipeline 
(Hodgkinson et al., 2008).  Four tagging SNPs (rs4813625, rs877172, rs3761248, 
rs2740210), located in noncoding regions just upstream/downstream to OXT, were 
genotyped using the Illumina GoldenGate platform (Hodgkinson et al., 2008).  Genotype 
frequencies and base changes are shown in Table 8.  Some genetic data was not available 
due to blood collection issues during the study (e.g. bad veins) or due to poor DNA 
quality; final sample sizes are listed in Table 8.  
 
Study Protocol 
 Given oxytocin’s anxiolytic effects and as changes in oxytocin plasma have been 
previously shown to be related to attachment anxiety (Turner et al., 1999; Turner et al., 
2002; Marazziti et al., 2006), subjects were administered the Adult Attachment 
Questionnaire (Collins and Read, 1990) prior to scanning.   
 Each subject underwent a 90 minute PET scan with [11C] raclopride, a DA 
radiotracer with affinity for both D2 and D3 receptors (Seeman et al., 2006). We 
employed a universal physical and emotional stressor, moderate levels of sustained pain, 
which has been shown to activate DA neurotransmission in the basal ganglia (Scott et al., 
2006). A steady state of muscle pain was maintained over 20 min from 45-65 min post-
tracer administration. This took place through a computer-controlled infusion of 
medication-grade hypertonic saline (5%) administered into the left masseter muscle.  Pain 
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intensity was rated every 15 seconds from 0 (no pain) to 100 (most intense pain 
imaginable) using an electronic version of 100mm visual analog scale (VAS). The 
individual ratings of pain intensity were employed by the computer controller to maintain 
constant pain in a manner comparable across subjects using a target of 40 VAS units, as 
previous described (Zhang et al., 1993; Stohler and Kowalski, 1999). Upon completion of 
the pain challenge, integrative measures of the experience were obtained using the 
McGill pain questionnaire (MPQ) (Melzack and Torgerson, 1971) and the Positive and 
Negative Affectivity Scale (PANAS) (Watson et al., 1988), the latter assessing the 
internal affective state of the participants. Preceding the pain stress challenge, subjects 
underwent a baseline control condition during which there was no expectation of pain 
and no infusions took place.  At the time of scanning, blood was taken to determine 
hormone levels (i.e. estrogen, progesterone, and testosterone). 
 
Neuroimaging methods 
 PET scans were acquired with a Siemens (Knoxville, TN) HR+ scanner in 3-D 
mode (reconstructed full-width at half maximum (FWHM) resolution (~5.5 mm in-plane 
and 5.0 mm axially).  Radiotracer synthesis and image acquisition, coregistration and 
reconstruction protocols were identical to those used in previous publications (Scott et al., 
2006). Briefly, images were reconstructed using iterative algorithms into a 128 x 128 
pixel matrix in a 28.8 cm diameter field of view. Attenuation correction was performed 
through a 6 min transmission scan (68Ge source) obtained before the PET study. Small 
head motions during emission scans were corrected by an automated computer algorithm 
for each subject before analysis, and the images were coregistered to each other with the 
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same software (Minoshima et al., 1993). Time points were then decay-corrected during 
reconstruction of the PET data.  
The total activity of [11C] raclopride administered to each subject was 15.0 ± 2.2 
mCi. Fifty percent of the [11C] raclopride dose was administered as a bolus with the 
remainder delivered as a continuous infusion by a computer-controlled automated pump 
to more rapidly achieve steady-state tracer levels. Under these conditions, equilibrium 
conditions across kinetic compartments are achieved approximately 35 min after tracer 
administration (Carson et al., 1997). 
 Twenty-eight image frames were acquired over 90 minutes with an increasing 
duration (30 seconds up to 10 minutes) and were coregistered to each other (Minoshima 
et al., 1993).  Dynamic image data for each of the receptor scans were transformed, on a 
voxel-by-voxel basis, into two sets of parametric maps, coregistered to each other: (a) a 
tracer transport measure (K1 ratio), and (b) a receptor-related measure at equilibrium 
(DVeq), the latter using data obtained from 35-45 min (control) or 60–80 min (pain 
stress) after tracer administration. DVeq -1 is proportional to Bmax/Kd, or binding potential 
at equilibrium (BPeq). This measure was obtained using the ratio of brain activity to 
activity in the cerebellum (Carson et al., 1997; Watabe et al., 2000). 
MRI scans were acquired on a 3 Tesla scanner (General Electric, Milwaukee, WI) 
for anatomical localization and coregistration to standardized stereotactic coordinates.  
Acquisition sequences were axial spoiled gradient-recalled (SPGR) [echo time (TE), 3.4 
ms; repetition time (TR), 10.5; inversion time, 200 ms; flip angle, 25°; number of 
excitations (NEX), 1; 124 contiguous images; 1.5 mm thickness].  
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T1-weighted MR and PET images of each subject were then coregistered to each 
other using a mutual information algorithm as previously described (Meyer et al., 1997). 
For this purpose, K1 images (containing anatomical information similar to that of regional 
cerebral blood flow scans) were first aligned to the MR, and the transformation matrix 
applied to the co-registered DVR scans of the same series. The MR scans were then 
anatomically standardized to ICBM brain atlas stereotactic coordinates by linear and non-
linear warping, and the resulting transformation matrix applied to K1 and DVR images 
(Meyer et al., 1997; Meyer et al., 1998). The accuracy of coregistration and warping 
algorithms were confirmed for each subject individually by comparing the transformed 
MRI and PET images to each other and the ICBM atlas template. 
 
Image Analyses 
 Activation of DA D2/D3 neurotransmission is detected as a reduction in BPeq 
(i.e. lower levels of in vivo DA D2/3 receptor availability during the challenge). This was 
calculated as the difference between the control state and the activated, pain stress state. 
Differences between groups for DA activation were mapped into stereotactic space using 
F maps of statistical significance with SPM2 (Welcome Department of Cognitive 
Neurology, University College, London) and Matlab software (MathWorks, Natick, MA), 
using a general linear model and correction for multiple comparisons (Friston et al., 
1995).  No global normalization was applied to the data, and therefore the calculations 
presented are based on absolute Bmax/Kd estimates. Only regions with specific DA D2/D3 
receptor binding were included in the analyses (voxels with BPeq values > 0.2).  To 
compensate for small residual anatomic variations across subjects and to improve signal 
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to noise ratios, a three-dimensional Gaussian filter (FWHM 6 mm) was applied to each 
scan.  
   Given the previously described sex differences in dopaminergic activity (e.g. 
(Munro et al., 2006; Riccardi et al., 2006a)) and the potential for sex differences in the 
effects of oxytocin, genotype effects were examined for males and females separately.  
Given the low frequency for some of the genotypes (rs2740210, TT; rs3761248, CC; 
rs4813625, CC; rs877172, CC), homozygotes for the rare allele and heterozygotes were 
combined.  Voxels of interest were then isolated using two-sample t-tests.  Each SNP was 
analyzed separately, to compensate for the four SNP comparisons the p value threshold 
used to detect significant differences was adjusted using the Bonferroni method from the 
standard 0.05 to 0.0125.  This was estimated using the Euler characteristic (Worsley, 
1994) based on the number of voxels in the gray matter and image smoothness (Friston et 
al., 1991).  Numerical values for each region were obtained by averaging the values of 
voxels contained in each significant cluster up to a p<0.001 level. These data were 
extracted for quantification of regional changes in BP, to rule out the presence of outliers, 




Stress-Induced Activation of DA Neurotransmission 
Two sample t-tests were employed to determine the presence of genotype 
differences in DA neurotransmission in males and females.   
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Using our conservative p value threshold of p < 0.0125 following FDR correction 
for multiple comparisons, significant differences between carriers of GG vs. GC/CC for 
SNP rs4813625 were noted within the right ventral striatum in our female sample (Table 
8, Figure 6).  Examination of the other three SNPs did not reveal any significant 
differences; however, effects were noted in the same region for SNPs rs3761248 and 
rs877172 albeit below our stringent a priori threshold (Table 1).  The similar effects 
noted for these three SNPs are consistent with the finding that these SNPs appear to be in 




Figure 6.  Impact of OXT rs4813625 on Stress-Induced DA Neurotransmission. Left. Results of two-sample t-test for the OXT SNP rs4813625 in the 
female samples showing greater release in the GC/CC group relative to the GG group within the right ventral striatum.  Right.  Bar graph of extracted data 












Table 8. Effects of Genotype on Stress-Induced Dopaminergic Activity  
    
  Females Males 
SNP Allele Info N 
x,y,z 
Coordinates, 
mm a T score b P b n 
x,y,z 
Coordinates, 





(TT=4, TG=10, GG=17) ----- ----- ----- 
n=17  
(TT=3, TG=6, GG=13) ----- ----- ----- 
rs3761248 C/T 
n=24  
(TT=19, TC=13, CC=0) 5, 19, 6 4.80 0.025* 
n=18  
(TT=14, TC=6, CC=3) ----- ----- ----- 
rs4813625 C/G 
n=20  
(GG=10, GC=12, CC=6) 5, 15, 1 5.48 0.010** 
n=18  
(GG=8, GC=12, CC=2) ----- ----- ----- 
rs877172 A/C 
n=24  
(AA=13, AC=16, CC=3) 4, 12, 2 3.32 0.001 
n=18  
(AA=10, AC=8, CC=5) ----- ----- ----- 
 
Table 8. Effects of Genotype on Stress-Induced Dopaminergic Activity a. Indicates the Montreal Neurological Institute coordinates b. Calculated using 2-
sample t tests for differences between genotype *P value after multiple comparisons correction (FDR) ** Significant differences detected between genotype 





Given the significant differences noted for the rs4813625 SNP, GG and GC/CC 
carriers were compared across multiple measures using two-sample t-tests to determine if 
there were any differences in demographics or their pain experience.   
There were no significant differences in any of the demographic or scanning 
variables tested (Table 9).  In addition, no differences were observed related to menstrual 
cycle in females or hormones (Table 9). Two-sample t-tests revealed significant 
differences in MPQ Pain Intensity (p = 0.048) and MPQ Affect (p=0.045) between GG 
and GC/CC carriers within our female sample. No other differences in psychophysical 











Table 10.  Psychophysical Measures  - rs4813625      
       
 Females Males 
 GG (n=10) GC/CC (n=18) P Value GG (n=8) GC/CC (n=14) P Value 
Average VAS intensity 31 (12) 38 (13) 0.153 34 (11) 32 (9) 0.745 
Total volume of hypertonic saline solution (5%) 2912  (1260) 2498 (1380) 0.440 2706 (1045) 2677 (1160) 0.955 
MPQ Pain Intensity 39.8 (11.8) 49.2 (11.3) 0.048* 43.1 (15.8) 40.6 (9.6) 0.641 
MPQ Pain Unpleasantness 46.5 (22.1) 48.6 (16.5) 0.776 47.5 (12.0) 42.8 (14.3) 0.440 
MPQ Sensory 15.9 (5.9) 15.4 (5.6) 0.822 16.8 (6.4) 16.1 (8.9) 0.867 
MPQ Affect 2.7 (1.8) 1.2 (1.9) 0.045* 2.1 (4.2) 1.6 (2.1) 0.682 
PANAS Negative Affect 2.0 (4.0) 1.1 (2.5) 0.474 -3.5 (9.4) 1.2 (11.6) 0.392 
PANAS Positive Affect 1.7 (5.7) 5.8 (5.3) 0.066 7.3 (4.1) 5.1 (6.3) 0.432 
Table 10.  Psychophysical Measures  - rs4813625 a. Data are expressed as mean (SD) b. Calculated using 2-sample t tests for differences between genotype * 
Significant differences detected between genotype groups.
Table 9. Demographics & Scanning Measures - rs4813625 
       
 Females Males 
 GG (n=10) GC/CC (n=18) P Value b GG (n=8) GC/CC (n=14) P Value b 
Age 26.2 (7.4) 26.6 (5.2) 0.865 26.5 (3.6) 25.2 (3.1) 0.386 
Dose (mCi) 15.3 (1.2) 14.8 (2.9) 0.587 14.8 (3.1) 15.2 (1.2) 0.666 
Testosterone (ng/mL) 62.8 (21.1) 48.7 (18.7) 0.097 601.2 (288.0) 604.0 (235.0) 0.982 
Estradiol (pg/mL) 106.3 (60.4) 94.2 (71.0) 0.669 ---- ---- ---- 





 We observed significant differences between GG and GC/CC carriers in 
attachment anxiety within our female sample (mean ± SD, GG, 46.1 ± 16.7, GC/CC, 63.6 
± 19.5; p=0.038) (Figure 3).  We did not detect any differences in attachment avoidance 
(mean ± SD, Females: GG, 45.6 ± 21.7, GC/CC, 50.7 ± 20.1; p=0.570) nor were any 
differences observed among the males (mean ± SD, Anxiety: GG, 54.8 ± 16.3, GC/CC, 
54.9 ± 18.0, p=0.982); Avoidance: GG, 41.8 ± 20.2, GC/CC, 49.2 ± 22.8, p=0.452). 
 
 
Figure 8.  Attachment Anxiety by Genotype in Females. Association of OXT rs4813625 genotype on 




 This study is the first to associate a gene polymorphism with differential 
dopaminergic responses to a stressor. We find that in females, carriers of the C allele for 
SNP rs4813625 of the oxytocin gene show greater DA responses to the pain stress 
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challenge relative to G homozygotes.  These same individuals, though receiving similar 
levels of hypertonic saline and reporting comparable VAS ratings during the challenge 
itself, recall greater pain intensity and ascribe more negative affective qualities to the pain 
immediately following the pain challenge.  In addition, C carriers display increased 
attachment anxiety.  We failed to find similar associations among the males in our 
sample, which may suggest a sex-specific effect of this gene. 
 Encoded by the OXT gene, oxytocin is initially synthesized as a precursor 
complex comprised of oxytocin and its carrier peptide neurophysin I.  During post-
translational processing, the oxytocin-neurophysin prohormone is cleaved to produce 
oxytocin and neurophysin (Land et al., 1983).  The first polypeptide hormone to be 
synthesized in a laboratory, oxytocin was first noted and utilized for its  labor and 
parturition effects which had been described more than a century ago (Dale, 1906; du 
Vigneaud et al., 1954)).  Further investigations into oxytocin, uncovered widespread 
effects capable of modulating complex processes including stress responsiveness.  In 
response to stress both central and peripheral mechanisms are engaged and oxytocin 
appears to affect both processes (e.g. (Lang et al., 1983; Jezova et al., 1995; Wotjak et al., 
1998)).  Oxytocin seems to be involved in the stress reduction process, having anxiolytic 
and antinociceptive effects upon release or administration (e.g. (Jezova et al., 1995; 
Robinson et al., 2002; Onaka, 2004)).  This effect of oxytocin has been often considered 
in the realm of maternal and affiliative behavior (see review (Lee et al., 2009)), whereby 
reduction of stress may be beneficial to the formation of social bonds; however, 
researchers have noted oxytocin-related reductions in stress responsiveness in stress 
paradigms which did not contain social elements such as forced swimming and osmotic 
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stress (e.g. (Lang et al., 1983; Kasting, 1988; Jezova et al., 1995; Wotjak et al., 1998; 
Neumann et al., 2000). 
 Here, we find that polymorphisms of the oxytocin gene are associated with 
reductions in stress-induced dopamine release in response to pain within the ventral 
striatum.  Increases in dopamine activity within the striatum following this pain challenge 
have been associated with more negative pain experiences (Scott et al., 2006).  Dopamine 
release within the ventral basal ganglia is particularly related to negative emotional 
responses; specifically greater stress-induced activity is positively associated with 
increases in negative affect and fear as reported by the PANAS (Scott et al., 2006).  This 
follows with this report, where female carriers of the C allele for SNP rs4813625 display 
the greatest dopamine release and report higher pain intensity and assign more affective 
qualities to the pain when compared to G homozygotes.  We did not, however, observe a 
similar effect in our male sample.  There is some evidence to suggest that oxytocin may 
affect men and women differently, for instance oxytocin and its receptor expression tend 
to be higher in females, show different distributions in males and females, and appear to 
be modulated by gonadal steroids in animal models (see (Insel and Shapiro, 1992; Gimpl 
and Fahrenholz, 2001; Nomura et al., 2002; Carter, 2007; Lee et al., 2009)). Whether 
oxytocin expression and distribution varies among sexes in humans has not been 
examined fully, however some data suggest there may be sex differences in its effects in 
humans.  For instance, oxytocin release has been shown to be triggered by empathy, more 
so in women than in men (Barraza and Zak, 2009). The paucity of data on sex differences 
in humans and the data presented here suggest that sex differences in oxytocin 
functioning should be further explored in humans. 
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 Finally, we noted a difference in attachment anxiety between C carriers and G 
homozygotes for SNP rs4813625, specifically, we note that C carriers display increased 
attachment anxiety relative to G homozygotes.  As mentioned earlier, oxytocin is known 
to modulate affiliative behavior; for instance, in humans intranasal administration of 
oxytocin has been shown to increase trust (Kosfeld et al., 2005; Baumgartner et al., 
2008), positive communication during couple conflict (Ditzen et al., 2009), social 
memory (Guastella et al., 2008a; Savaskan et al., 2008; Rimmele et al., 2009), eye gaze 
(Guastella et al., 2008b), use of social cues to infer mental state (Domes et al., 2007), and 
maternal behavior (Feldman et al., 2007). Consistent with our findings here, previous 
studies have noted associations between changes in oxytocin plasma and attachment 
anxiety in humans (Turner et al., 2002; Marazziti et al., 2006). Oxytocin receptor 
polymorphisms have been shown to be associated with autistic disorders, where a 
significant impairment of attachment behavior has been noted (Wu et al., 2005; Jacob et 
al., 2007; Lerer et al., 2008; Wermter et al., 2009) and with adult attachment style in 
depressive patients (Costa et al., 2009).  In regards to the direction of our findings we 
note a pattern of antistress: we note lower attachment anxiety in the same group of 
individuals (G homozygotes) who also exhibited the least stress-induced DA release and 
recalled the least distress following the pain challenge.  Given oxytocin anxiolytic 
properties, this may suggest greater oxytocin functioning in this group however further 
studies are needed to determine the exact source of the differences observed here. 
 This study represents preliminary research into oxytocin genetic influence on pain 
and stress responses.  Our data suggests the oxytocinergic system may be involved in 
dopaminergic stress mechanisms in humans.  We note that oxytocin is much more than a 
102 
 
social and reproductive hormone, rather it has larger more disparate effects and it appears 
to influence central stress processes in humans.  The mechanism by which we see our 
effects is unknown, however, it is likely a yet undiscovered nearby polymorphism which 
is in LD with this SNP confers sex-specific variability in DA responses to stress by 
influencing the expression, posttranslational processing or function of oxytocin or it’s 
carrier protein neurophysin.  Further work is needed to determine what processes are 
involved.  This study is of particular interest in regards to psychiatric disorders, such as 
addiction, whereby stress induced dopamine release is thought to be related to its 
neuropathology.  Interestingly, oxytocin may impart resilience to drug addiction and has 
been previously observed to inhibit tolerance, physical dependence and attenuate relapse 
(see (Kovács et al., 1998).  To conclude, we find that genetic variation in the OXT gene 
may be relevant in the formation of individual variability in dopamine functioning; 






It has been hypothesized that drug abusers may be biologically predisposed to use 
and abuse drugs (Piazza et al., 1998b).  How factors typically associated with increased 
risk relate to this biological predisposition however is not well understood.  While some 
individuals appear to be ‘spontaneously predisposed’ as perhaps a result of genetic 
factors others may become vulnerable as a consequence of interacting genetic and 
environmental agents interfering with key neurobiological processes (Piazza et al., 
1998b).  
As Piazza, LeMoal and other researchers have described, there are two main 
theoretical perspectives to describe why individuals are motivated to use drugs:  
individual-centered, drug-centered.  In the drug-centered view, paramount to the cause of 
addiction are drug-induced alterations to key neural pathways that put an individual at 
risk for compulsive use. Alternatively, in the individual-centered view, biological 
characteristics unique to a person leave them in a vulnerable state to the effects of drugs; 
thus addiction is not solely a result of the drug effects on brain activity but interacts with 
underlying biological susceptibilities (Piazza and Le Moal, 1996; Piazza et al., 1998b; 
Piazza et al., 1998a; le Moal, 2009).   
Taking individual differences into account, multiple factors, some inherited (i.e. 
genetics) and some acquired (e.g. stress), interact to produce a vulnerable phenotype that 
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exists prior to the initiation of drug use.  Given this, it should be possible to observe 
differences in functioning that are related to an individual’s risk.  Unfortunately, 
identifying such differences in humans prior to the onset of addiction has been hampered 
by methodological difficulties and much that we know regarding addiction vulnerabilities 
comes from the study of animals or current and former drug addicts.  Though not ideal, 
studying animals or examining humans diagnosed with substance abuse or dependence 
do provide some perspective as to the neurobiological alterations that occurred either as a 
result of chronic drug use or that may have predisposed them to drug use initially. These 
studies have established that alterations within the stress and motivational circuitry can 
contribute to the development of addiction. An alternative approach to studying substance 
use vulnerability involves studying a population that carries risk factors that are 
hypothesized to place them at a higher risk but who have no history of substance 
dependence or abuse.  This allows for the characterization of neurobiological activity as a 
function of risk without concern for previous chronic drug use. 
The work presented here attempted to ascertain whether and how particular 
susceptibility characteristics identified as risk factors resulted in variation in 
neurobiological functioning in healthy, non-drug using individuals.  We demonstrated 
relationships between dopaminergic and opioidergic activity with multiple factors 
relating to substance abuse vulnerability.  Genetic, environmental and trait characteristics 
were all observed to influence activity within regions in the motivational circuitry, 
particularly within the ventral striatum.  In sum, we extended and clarified previously 
described differences in dopaminergic activity between men and women, noting a 
significant interaction with environmental factors.  Next, genetic variation within the 
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oxytocin receptor was found to predict variation in dopaminergic activity within the 
ventral striatum.  Finally, we demonstrated that trait characteristics, specifically measures 
of non-planning impulsivity, are associated with µ-opioid receptor activity, expanding 
upon the former literature previously describing an association with dopaminergic 
functioning.  
Animal work done nearly twenty years ago highlighted alterations within the 
brain’s motivational circuitry and in stress system functioning in animals predisposed to 
self-administer drugs.  Piazza and colleagues recognized that individual differences in 
stress-reactivity predicted self-administration behavior (e.g. (Piazza et al., 1989; Piazza et 
al., 1990b; Piazza et al., 1998a)). Later it would be demonstrated that by modulating 
stress reactivity, self-administration behavior could be manipulated. In addition, stress 
was shown to have the capacity to sensitize behavioral and neurochemical responses to 
psychostimulants and vice-versa (Antelman et al., 1980; Deroche et al., 1992; Piazza and 
Le Moal, 1996; Deroche et al., 1997).  Given these observations, specifically that 
vulnerability to seek and use drugs is related to individual differences in stress reactivity 
and could be critical to identifying the presence of a vulnerability characteristic, we chose 
to examine the effects of susceptibility factors on neurochemical activity following a non-
pharmacological stress challenge, pain-stress.  
Pain is a universal stressor and is frequently used to provoke stress responses in 
animals and humans alike.  For the challenge employed here, pain was administered over 
twenty minutes by the infusion of 5% hypertonic saline into the masseter muscle within 
the jaw via a computer-controlled pump.  By recording pain intensity every fifteen 
seconds, we are able to adjust the infusion of hypertonic saline and maintain pain at a 
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constant level using a target of 40 VAS units (Zhang et al., 1993; Stohler and Kowalski, 
1999).  Hence, we are able to ensure that all subjects share a similar pain experience 
despite differences in pain sensitivity. This challenge has been shown to produce robust 
activations within both the endogenous opioid and dopaminergic systems, though there is 
a high degree of interindividual variability (e.g. (Zubieta et al., 2001; Scott et al., 2006)). 
These previous observations are in line with research describing the recruitment of 
multiple neuronal pathways in response to stress, presumably activated to allow an 
individual to adapt to the challenge.  Research performed to date has provided significant 
information towards understanding the neurobiological aspects of the stress response, 
though less is understood of the nature and consequences of individual differences in 
these responses. In this work, we find a significant portion of this variability can be 
explained by factors identified for substance abuse risk.  
 
Dopaminergic System Variation 
Sex and Stress Effects 
Our results obtained in a sample of healthy, college age men and women observed 
a significant contribution of sex in determining dopaminergic responses to stress.  This 
was the first study to demonstrate sex differences in response to a pain-stress challenge in 
humans.  Utilizing [11C] raclopride labeled PET, we obtained measures of D2/D3 
receptor activity during the pain-stress challenge described earlier. Examining 
dopaminergic activity following our challenge, females exhibited significantly greater 
stress-induced dopaminergic activity when compared to males in regions throughout the 
striatum, though notably within the nucleus accumbens.  This is interesting given 
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previous research indicating that enhanced dopaminergic activity within the mesolimbic 
dopamine system is associated with greater drug use (Rouge-Pont et al., 1993; Piazza and 
Le Moal, 1997; Piazza et al., 1998b; Rouge-Pont et al., 1998; Marinelli and Piazza, 2002) 
and that females appear to more rapidly progress from initiation to compulsive drug use 
compared to men (see (Becker et al., 2007)) . The differences in dopaminergic stress 
responsivity noted here might be an important underlying factor in determining later 
substance use risk.   
The precise mechanisms whereby our sex differences in dopaminergic 
responsivity emerged are not clear.  Though we did not observe any relationships 
between gonadal hormone levels and dopaminergic activity, the effect of circulating 
hormones should not be entirely discounted.  Our sample size was somewhat small and 
excluded females in their luteal phase.  Obtaining larger sample sizes and sampling 
dopaminergic activity over the course of the menstrual cycle would help determine 
hormonal influence on dopaminergic activity.  Certainly such influences would be 
predicted based on multiple lines of research described earlier.  For example, previous 
research indicates different behavioral responses to dopaminergic drugs across the 
menstrual cycle (Justice and de Wit, 1999; Sofuoglu et al., 1999; White et al., 2002)). 
Continuing in this work, we further uncovered a significant interaction between 
sex and environment in determining dopaminergic stress responses.  Prior to scanning, all 
subjects were instructed to complete an inventory that presented a series of common life 
events and asked the subject to indicate which events occurred within the last year.  
Subjects were divided into those that had experienced recent negative life stress (RLS) 
and those who had not (NoRLS). We then compared stress-induced dopaminergic activity 
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between the RLS group and the NoRLS group incorporating sex into the model.  What 
we observed could be interpreted as an overall blunting of the stress response.  Whereas 
significant differences between control and pain conditions were observed in the NoRLS 
men and NoRLS women, no such differences were recorded between control and pain 
conditions in either RLS group.  A net dampening of dopaminergic responsiveness as a 
result of persistent or chronic stress has been previously observed.  Some chronic stress 
protocols in animal models have also been shown to elicit significant decreases in 
dopaminergic activity within accumbens and in certain forebrain areas (e.g. (Gambarana 
et al., 1999; Mangiavacchi et al., 2001; Scheggi et al., 2002)).  We may be observing 
neurobiological adaptations within the mesolimbic dopamine system as a result of 
exposure to recent life stress. Previous research has demonstrated that exposure to stress 
can place an individual at greater risk to use and abuse drugs.  This work indicates that 
exposure to recent stressful life events can influence dopaminergic stress-responsivity 
measures.  It is possible that disruptions in dopaminergic responsivity as a result of 
historical stress may partially account for increased risk for substance use. 
 
Sex and Genetic Effects  
In the next set of experiments, we examined data collected from a larger set of 
men and women, which had undergone [11C] raclopride scanning during which time 
blood was collected and genotyped. Polymorphisms in the oxytocin gene were examined 
to determine if genetic variation at this gene could predict differences in stress induced 
dopaminergic activity. The choice to study oxytocin gene polymorphisms came as a 
result of extensive research indicating that oxytocin has broad effects on a wide range of 
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behavior in reproductive, affiliative and motivational realms.  In addition, oxytocin has 
been shown to alter dopaminergic responses associated with addictive behaviors and 
stress (e.g. (Pfister and Muir, 1989; Sarnyai and Kovács, 1994)).   
We examined oxytocin genotype in relation to changes in dopaminergic activity 
in response to our pain-stress challenge.  Given our previous findings that sex influences 
dopaminergic activity and the potential for sex differences in the effects of oxytocin, 
genotype effects were examined for males and females separately. We observed that 
carriers of the C allele for SNP rs4813625 of the oxytocin gene exhibit greater DA 
responses to the pain stress challenge relative to G homozygotes – this relationship was 
only noted in females. Female carriers of the C allele also recall greater pain intensity, 
assign more negative affective qualities to the pain immediately following the pain 
challenge and demonstrate higher levels of trait attachment anxiety. Why these effects of 
oxytocin genotype were only observed in our female sample is not entirely clear, 
however oxytocin is observed to have sex specific effects on behavior (e.g. maternal 
behavior).  Another possibility is that due to our relatively small sample of males, we 
lacked sufficient power to resolve such genotype differences in our males.  
Since the SNPs identified for the oxytocin gene were outside of the coding region 
and this is the first investigation examining their relationship to behavior or 
neurobiological functioning, the means whereby we observe our effects is not known.  It 
is possible that rs4813625 is in linkage disequilibrium with a functional polymorphism 
that mediates alterations in stress or dopaminergic activity.  Given that oxytocin has been 
frequently demonstrated to possess anxiolytic properties (e.g. (Windle et al., 1997; 
Neumann et al., 2000; Heinrichs et al., 2003; Ring et al., 2006; Ditzen et al., 2009)) it is 
110 
 
tempting to speculate that our observation may reflect greater or more efficient 
functioning of oxytocin in our G carriers.  Future studies will need to determine the exact 
genetic mechanisms behind the observations noted here. 
 
Mu-Opioid System Variation 
Previous epidemiological studies, as described in detail earlier, have suggested 
trait characteristics, particularly trait impulsivity, are important factors in determining 
future drug use and abuse. Given that several reports have previously demonstrated 
effects of sensation seeking and impulsiveness traits on dopaminergic activity in humans 
(Leyton et al., 2002; Boileau et al., 2006; Riccardi et al., 2006a; Oswald et al., 2007), we 
chose to examine the influence of trait impulsivity on a different neurotransmitter system, 
the opioid system.  We examined data collected from a healthy group of college-aged 
males which had been administered the NEO personality inventory then subsequently 
underwent [11C] carfentanil imaging.  Subjects were grouped based on their impulsivity 
and deliberation ratings and compared on their µ-opioid system response to the pain 
challenge described earlier.  
Though dopamine is the best studied in regards to reward, motivation and 
substance abuse, mesolimbic dopamine activity is heavily modulated by other 
neurotransmitter systems.  The µ-opioid system interacts with the mesolimbic dopamine 
system both directly and indirectly. µ-opioid receptors are present throughout the 
motivational circuit including on GABAergic interneurons within the VTA and on 
medium spiny GABAergic neurons within the nucleus accumbens that project back to the 
VTA. The µ-opioid system can also modulate activity within the mesolimbic circuitry 
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indirectly through its actions on HPA stress responses. Endogenous opioids can attenuate 
stress responses, whereas opioid receptor blockade can result in disinhibition of the HPA 
axis leading to release of cortisol and adrenalcorticotropin hormone (Janssens et al., 
1995; Wand and Schumann, 1998; Geer et al., 2005). µ-opioid activity can also modulate 
the expression of stress-responsive genes within the hypothalamus and anterior pituitary.  
In addition, µ-opioid activity can inhibit neurons within in the locus coeruleus that 
normally stimulates hypothalamic CRH (Wand and Schumann, 1998).   
The µ-opioid system is capable of modulating the mesolimbic dopamine pathway, 
and is central to the regulation of motivated behavior.  In sum, given the relevance of the 
µ-opioid system, we explored how individual differences in impulsivity, a known 
susceptibility factor for substance use and abuse, were associated with µ-opioid system 
activity. 
We examined two orthogonal traits that relate to the non-planning dimension of 
impulsivity:  NEO Impulsiveness (IMP) and NEO deliberation (DLB).  We found that 
individuals displaying high IMP or low DLB had greater µ-opioid receptor availability at 
rest and greater stress-induced activity within regions involved in motivated behavior and 
the effects of drugs of abuse: prefrontal cortex, anterior cingulate, thalamus, basolateral 
amygdala, and, notably, the nucleus accumbens.  In order to determine how the 
combination of the two behavioral traits could influence µ-opioid receptor availability 
and responses to stress we performed a conjunction analysis; this revealed that 
individuals exhibiting extreme traits (high IMP/low DLB and low IMP/high DLB) 
displayed the greatest and smallest baseline µ-opioid receptor availability and stress-
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induced activity, respectively.  These findings come in absence of any difference in the 
experience of pain itself between high/low IMP or high/low DLB groups.   
Our observations in humans are in line with previous research indicating HR rats, 
which show greater stress-reactivity, a propensity to self-administer drugs and greater 
dopaminergic responses to drugs, display increased nucleus accumbens proenkephalin 
gene expression (Lucas et al., 1998).  We would anticipate similar disparate effects 
between high/low IMP and high/low DLB groups in stress-induced dopaminergic 
activity.  In fact, the differences in dopaminergic activity the HR group have been 
hypothesized to result at least partially, from the higher enkephalin tone seen within the 
nucleus accumbens (Lucas et al., 1998).  Whether our high IMP/low DLB individuals 
also differ in dopaminergic activity is not yet known though several investigations have 
noted positive relationships between novelty seeking and impulsivity with dopaminergic 
activity in the ventral striatum (Leyton et al., 2002; Riccardi et al., 2006a) however, these 
findings are somewhat inconsistent, with some reporting negative relationships (Riccardi 
et al., 2006b; Riccardi et al., 2006a; Oswald et al., 2007).  All of the aforementioned 
studies utilized pharmacological interventions as a means to increase dopaminergic 
release, so examining the association between these traits and stress-induced dopamine 
activity would be of some interest.  In particular, it would be of much use to see how 
dopamine and opioid activity in the same individuals are affected by trait characteristics 
to develop a more complete picture.  
In conclusion, this work was the first to provide evidence that µ-opioid system 
functioning is associated with personality traits identified as susceptibility factors to 





There does not appear to be any one factor unique to producing drug abuse. 
Understanding how susceptibility factors relate to differences in underlying 
neurobiological functioning may lead to a better understanding of how these elements 
convey risk to substance abuse and a better comprehension of what is shared among those 
vulnerable to use.  The results from this body of work find that various neurochemical 
responses to stress within the motivational circuitry are influenced by certain 
susceptibility factors.  Specifically, as a whole we find that individual characteristics 
related to substance abuse risk are somewhat predictive of dopaminergic and opioidergic 
responses within the ventral striatum to stress. This region is critical in determining not 
only the reinforcing effects of drugs but in determining motivated behavior in general.  
Enhanced dopaminergic activity within the ventral striatum in response to mild 
stress has been shown to be predictive of later self-administration behavior (see (Piazza et 
al., 1998a)).  Indeed, Piazza and others have directly postulated that individuals 
presenting higher dopaminergic activity may be at higher vulnerability to self-administer 
drugs (Piazza et al., 1998b). Related to this, enhanced enkephalin tone at this region 
could also be a contributory factor (Lucas et al., 1998). We note within our sample that 
females in general and particularly carriers of the C allele for rs4213625, demonstrate the 
highest greater stress-induced dopaminergic activity within the right ventral striatum. 
Similarly, within this same region males exhibiting high levels of impulsiveness show 
enhanced stress-induced µ-opioid system activation.  Research suggests that increased 
opioidergic and dopaminergic activity within this region could potentially positively 
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influence individual assessments of rewarding stimuli like drugs of abuse – could this 
partially underlie the previous epidemiological demonstrations of increased risk to use 
drugs in the groups studied here?  This may be possible, however, the work presented 
here represents a preliminary step towards understanding the neurobiological 
mechanisms underlying vulnerability.  It would be of significant interest to determine if 
variation in ventral striatal opioidergic and dopaminergic functioning is indeed predictive 
of later drug use in humans, however much more preliminary work is needed before 
direct connections between susceptibility factors, future drug use and neurobiological 
activity can be established.  First, given the ample evidence suggesting differences in 
HPA axis functioning among animals predisposed to self-administer drugs of abuse, the 
relationships between some of the dopaminergic and opioidergic measures obtained here 
should be linked to cortisol activity during the challenge.  Second, future studies should 
attempt to determine how the presence of multiple susceptibility factors influences 
functioning in this circuit – Do different factors have distinct effects, or do they, as some 
data collected here suggests, have additive effects within similar regions? How does the 
interplay between different neurotransmitter systems reflect the expression of these 
factors? If risk can be modified (e.g. teaching of coping strategies) how does this affect 
the previously noted relationships? 
There is an important point to consider when linking the observations made here 
to substance abuse vulnerability – Though we note associations between neurochemical 
activity and susceptibility characteristics associated with risk for substance abuse 
problems, these susceptibility factors could also play a role in vulnerability for other 
psychopathological disorders (e.g. PTSD, major depressive disorder).  However, it should 
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be noted that the neurobiological circuitry disrupted in psychiatric disorders like PTSD 
and MDD are not entirely separable from the pathways disturbed in addiction; in fact, 
this may be why mental illness so frequently co-occurs with substance abuse problems 
(SAMHSA, 2009). Evidence suggests that psychiatric disorders and addiction share 
common neurobiological variation possibly within the motivational and stress systems 
(Volkow, 2001; Volkow, 2009).  It will be important to discover how susceptibility 
factors are represented in diseased populations and determine if similar neurobiological 
variation is observed. 
  
Final Comments 
People vary widely in their propensity to initiate and maintain drug use.  
Understanding the mechanisms that underlie the predisposition to seek out and use drugs 
is of significant importance in developing strategies to mitigate drug use before and after 
initial consumption.  These investigations extend previous research that outlined the 
neurobiological pathways associated with the effects of drugs of abuse and which 
appeared to be disrupted as a result of the addiction process.  This work reveals that some 
of the characteristics identified as risk factors for substance use are associated with 
biological processes previously identified as playing critical roles in the development of 
addiction (for summary, see Figure 9).
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Figure 9.  Summary of potential mechanism involved in drug abuse vulnerability.  Innate factors in interaction with 
environmental circumstances such as stress exposure determine responsivity of various neural substrates to external stimuli (e.g. 
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